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1. Diagnostics 
1.1. Introduction 
 
The first genetic test was run in 1978 by Kan and Dozy and independently by Orkin et 
al. The molecular testing was performed to detect the mutation c.20A>T in the β-globin DNA 
responsible for sickle cell anaemia. Kan and Dozy applied restriction analysis of the β-globin 
gene followed by hybridisation with a molecular probe complementary to the fragment of 
human β-globin sequence (RFLP method) [1]. Results enabled them the discrimination 
between mutant homozygotes (affected persons), normal homozygotes (healthy persons) 
and heterozygotes (mutation carriers). To detect the same mutation, Orkin et al. applied 
hybridisation with two variant oligonucleotide molecular probes to distinguish between 
mutant and normal alleles of the β-globin gene [2]. A milestone in development of molecular 
diagnostic techniques for detection of human mutations was the invention of polymerase 
chain reaction (PCR) made in 1983 by Kary Mullis. The PCR in molecular diagnostics is 
generally used to amplify DNA fragment before other molecular analyses are performed. 
Genetic testing is divided in two categories: direct testing and indirect testing (gene 
tracking). Direct genetic testing involves testing for a certain genotype, i.e. identification of a 
specific pathogenic mutation within a gene, that is responsible for a certain condition. 
Indirect genetic testing also known as gene tracking tests the inheritance and segregation of 
genetic markers linked to a specific condition within a family. 
 1.2. Nomenclature of mutations 
 
To describe sequence variations in a specific gene, a reference sequence should be 
used and its accession number from a database, such as Genebank, EMBL etc., should be 
specified in a publication. 
Mutations at DNA level are preceded with letters denoting the type of reference 
sequence used to describe the mutation, i.e. description of a mutation is preceded with “g.” 
if genomic DNA is used as a reference sequence or with “c.” if cDNA is used as reference 
sequence or with “m.” if  mitochondrial DNA is used as reference sequence. Sequence 
changes are described in upper case letters using A (adenine), C (cytosine), G (guanine) and T 
(thymine) to describe bases. Numbering of nucleotides begins with nucleotide +1 which is 
the A of the ATG codon (translation initiation codon). The previous nucleotide to the +1 
nucleotide is described as -1 nucleotide (there is no 0 nucleotide). In case of intronic 
sequences, for the beginning of an intron, the description begins with the number of last 
nucleotide of the preceding exon, the “+” sign and the position in the intron (e.g. c.78+1G). 
For the end of an intron the description begins with the number of the first nucleotide of the 
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following exon, the “-“ sign and the position located in the intron (e.g. c.79-1A). See Table 1 
for general recommendations for description of mutations at DNA levels. 
 Table 1. General recommendations for description of mutations at DNA level. Based on ref. [3]. 
Depending on the type of reference sequence the description must be preceded with “g.”, “c.” or 
“m.” 
Type of change Sign Example Description 
Substitution > 38A>C Nucleotide 38 is changed from A to C 
Deletion del 38_40del  
(or 38_40delAGT) 
Nucleotides from 38 to 40 (which are AGT) 
are deleted  
Duplication dup 38_40dup 
(or 38_40dupAGT) 
Nucleotides from 38 to 40 (which are AGT) 
are duplicated 
Insertion ins 38_39insT Nucleotide T is inserted between 
nucleotides 38 and 39 
Two changes in 
one allele 
[  ;  ] [38A>C; 77_79del] In the same allele, nucleotide 38 is changed 
from A to C and three nucleotides from 77 
to 79 are deleted 
Combined 
heterozygotes 
[  ]+[  ] [38A>C]+[ 77_79del] In one allele of the gene, nucleotide 38 is 
changed from A to C and in the second allele 
of the gene, there is a deletion of three 
nucleotides form 77 to 79 
 
Mutations at RNA level are generally described using the same rules as for DNA, 
except that the description of a mutation is preceded with “r.” that denotes for an RNA 
reference sequence (e.g. r.36u>a). Sequence changes are described in lower case letters 
using a (adenine), c (cytosine), g (guanine) and u (uracil) to describe bases, e.g. r.36u>a 
describes substitution of uracil at positons 36 with adenine. If a mutation results in two or 
more transcript production it should be described in brackets, e.g. [r.=, 73_88del] denotes 
that a nucleotide change in DNA results in production of one transcript of the normal 
sequence (r.=) and the second transcript with a deletion of nucleotides from 73 to 88 [3]. 
Mutations at protein level are generally described using the same rules as for DNA, 
except that the description of a mutation is preceded with “p.” that denotes for a protein 
reference sequence. Sequence changes are described in capitals and one letter amino acid 
code is preferred. Numbering of amino acids begins with the first methionine (+1 amino 
acid). See Table 2 for general recommendations for description of mutations at DNA levels. 
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Table 2. General recommendations for description of mutations at protein level. Based on ref. [3]. 
Type of change Sign Example Description 
Substitution  p.K20C Missense change; lysine 20 (K) is changed to 
cysteine (C) 
 X (stop 
codone) 
p.K20X Nonsense change; lysine 20 (K) is changed to 
a stop codon (X) 
Deletion del p.K20del Deletion of one amino acid (lysine, K) at 
position 20 
p.K20_M22del Deletion of three amino acids from lysine 20 
to methionine 22 
Duplication dup p.G31_C33dup Three amino acids from glycine 31 to 
cysteine 33 are duplicated 
Insertion ins p.K20_M21insQ Insertion of glutamine (Q) between amino 
acids lysine 20 (K) and methionine 21 (M) 
p.K20_M21insQCS Insertion of three amino acids glutamine 
(Q), cysteine (C) and serine (S) between 
amino acids lysine 20 (K) and methionine 21 
(M) 
Initiating 
methionine 
(M1) 
p.? p.? The effect of mutation on the protein level 
is unknown. 
p.0 p.0 The mutation results in no protein 
production 
Frameshift 
mutation 
fs (or fsX) p.R67fsX78 fs is placed after the first affected amino 
acid and the new reading frame ends with 
the amino acid 78. 
Variability of 
short sequence 
repeats 
(  )x-y 33(Q)6-9 The amino acid glutamine 33 is repeated 6 
to 9 times in the population 
 
 1.3. Samples for genetic testing. Collecting, transport and storage 
 
A wide range of biological samples may be used as a source of genetic material for 
molecular diagnostics. The most common type of sample obtained from an adult individual 
is blood sample which is a very good source of DNA or RNA for molecular diagnostics. 
Alternative to blood samples are Mouthwashes or buccal scrapes that may be collected very 
noninvasively and these samples are useful in population screening studies. To obtain fetal 
DNA, chorionic villous biopsy or amniotic fluid samples can be used. One or two cells 
removed from eight-cell stage embryos are used in case of pre-implantation genetic testing 
during in vitro fertilisation procedures (IVF). Dried blood spots (Guthrie card samples), i.e. 
blood samples blotted and dried on filter paper, are used in neonatal screening for genetic 
disorders. Tissues from biopsies or cultured cells are also used as a source of target DNA or 
RNA. Archived pathological specimens (e.g. Formalin Fixed Paraffin Embedded Tissue, FFPE) 
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are used in molecular testing of tumours or to obtain DNA of dead people. Hair or semen are 
used for molecular studies in criminal investigations [4, 5]. 
Before any genetic testing may be performed, an informed consent must be 
obtained form all participants and they need to be informed about any current, future and 
unforeseen usage of their samples. 
Stability of collected biological samples may be affected by many different factors, 
e.g. anticoagulants in collection tubes, stabilizing agents, temperature, timing before initial 
processing takes place, sterility, endogenous degrading properties (enzymes, cell death) etc. 
[5]. For example, citrate-stabilized blood may afford better quality of RNA and DNA than 
other anticoagulants would, also, EDTA is good for DNA-based assays, but it will influence 
Mg2+ concentration, and it may interfere for example with cytogenetic analyses [5].  
Many biochemical biomarkers may be affected by enzymatic degradation. Proteins 
are sensitive to degradation by proteases. To prevent degradation of proteins, specific 
commercially available protease inhibitors (e.g. aprotinin, pepstatin, antipain, leupeptin, or 
benzamidine) should be added immediately after collection of samples. Additionally, 
handling with proteins must be lead on ice. RNA is sensitive to degradation by RNases, thus 
RNase inhibitors should be added immediately after collecting before the sample will be 
processed. RNA stabilization reagents are available commercially (e.g. RNA later) and are 
very useful, if RNA isolation needs to be postpone for days, weeks or months after specimen 
collection. The reagent immediately stabilizes RNA in samples and preserves the gene 
expression profile. Additionally, all steps of handling with RNA require RNAse-free 
containers, equipment, enzymes etc. to prevent degradation and are important for 
maximizing the yield and quality of RNA preparation [5]. 
In case of some tests available only in certain reference centres, collected samples 
must be transported over long distances. To obtain a high quality DNA or RNA, collected 
biological samples should be stored in proper conditions. Depending on the type of sample 
to be shipped, samples may be shipped on wet ice or even at room temperature if shipped 
overnight [5]. 
Temperature affects sample stability during the time between sample collection and 
sample processing and during short and long-term storage. For example, isolated DNA 
may be stored at +4°C for several weeks, at -20°C for several months and isolated RNA must 
be stored at -80°C. Live cells are stable at room temperature for up to 48 hours but must be 
either cultured or cryopreserved in liquid nitrogen. Finally, long-term storage (for many 
years) may affect the integrity of nucleic acids. Both DNA and RNA must be stored at -80°C. 
Multiple aliquots of a sample are necessary, to avoid repeated freezing and thawing in order 
to prevent loss of the entire sample due to cross-contamination. Importantly, frost-free 
freezers must be avoided because they cause small volumes of aliquots to dry, even in 
capped tubes [5]. 
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 1.4. Methods in molecular diagnostics of human genetic disorders 
 
Some molecular diagnostic methods are used to test for presence of a specific, 
known DNA sequence change within a gene. These methods include for example PCR-RFLP, 
ASO, ASA, OLA and are especially useful in testing for genetic disorders showing limited 
allelic heterogeneity, in molecular diagnostics within a family or in research population 
studies. But some other genetic disorders are characterized by allelic heterogeneity, thus 
mutation screening methods, that test for any mutation, anywhere within the specific gene, 
are frequently used in the first place in molecular diagnostics. Most commonly used 
screening methods include SSCP and heteroduplex analysis. Screening diagnostics may be 
followed by sequencing of the gene to seek for the exact nucleotide change (mutation) [4].  
 
1.4.1. Restriction Fragment Length Polymorphism Analysis of PCR-Amplified Fragments 
(PCR-RFLP) 
 
PCR-RFLP is a method that couples PCR amplification with restriction analysis of 
produced DNA fragment. This technique, also known as cleaved amplified polymorphic 
sequence (CAPS), is very useful in genotyping. Single nucleotide polymorphisms (SNP) often 
create or abolish specific restriction sites, thus a specific nucleotide variation in this position 
may be detected using restriction endonucleases that recognize such sites. First, a specific 
fragment of a gene containing the variation is amplified by PCR. Next, the fragment is 
digested with an appropriate restriction enzyme and digestion products are resolved by 
agarose or acrylamide gel electrophoresis [6]. Depending on the presence or absence of 
investigated sequence variation, the PCR products digested by restriction enzyme will give 
readily distinguishable patterns after electrophoresis (Fig. 1). 
 
 
Fig. 1. An example of genotyping based on PCR-RFLP assay. 
 
allele 1
allele 2
Aa heterozygoteAA homozygote aa homozygote
1 2 3 4
Lane 1 – undigested PCR product
Lane 2 – AA homozygote
Lane 3 – aa homozygote
Lane 4 – Aa heterozygote
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A modification of previously described CAPS method is Derived Cleaved Amplified 
Polymorphic Sequences (dCAPS) method where PCR primer possesses a mismatched 
nucleotides in order to create a restriction site if a specific nucleotide change occurs in the 
target sequence.  
Genotyping based on PCR-RFLP is quite inexpensive and easy to design (there are 
programs for the design of PCR-RFLP), which is an advantage of this method, but the exact 
genotyping cannot be achieved if there is more than one nucleotide variation in a restriction 
enzyme recognition site. The procedure is relatively time consuming, because the full 
analysis consists of several steps [6]. 
 
1.4.2. Allele Specific Oligonucleotide (ASO) hybridization 
 
Allele specific oligonucleotide (ASO) analysis is a hybridization method for detection 
of point mutations or few base pair changes. Oligonucleotide probes used in ASO 
hybridization comprise 15-20 nucleotides and are complementary to sequences spanning 
the variant nucleotide site. Hybridization is run in very strict conditions so that the probe 
hybridizes with target DNA sequence only if there is a perfect base matching. If a single 
mismatch between probe and target DNA occurs (Fig. 2), the probe-target heteroduplex is 
very unstable at highly strict hybridization conditions and detection is possible only if there is 
a perfect match between probe and target. Oligonucleotide probes are labelled with 
radioactive, enzymatic or fluorescent tag to enable further detection of hybridization [4, 7]. 
 
Fig. 2. Alelle specific oligonucleotide (ASO) hybridization scheme. 
 
Allele-specific oligonucleotide (ASO) hybridization is rapid and efficient method for 
screening of known and most common mutations in a specific gene. For example in cystic 
fibrosis, ASO hybridization is used to detect the most common mutation F508del in the CFTR 
gene. Two ASO probes spanning the mutation site are designed, one complementary to the 
normal allele and the other to the mutant allele (i.e. sequence with deletion of AGA 
G
C
A
C
Perfect match between ASO 
probe and target DNA
Hybridization
Mismatch between ASO 
probe and target DNA
No hybridyzation
G
CASO probe
Target DNA 
(normal) A
C ASO probe
Target DNA 
(mutant)
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nucleotides). The PCR-amplified genomic DNA of tested individuals is spotted in duplicate 
onto a dot-blot hybridization membrane, next, either normal or mutant ASO probe is added 
and hybridization is detected, depending on the labelling tag of the probe (Fig. 3). Similarly, 
ASO hybridization is commonly used to detect the point mutation at codon 6 (GAG to GTG) 
in the HBB gene coding for β-globin in sickle cell anaemia.  
 
 
Fig. 3. Schematic dot-blot hybridization of allele specific oligonucleotide (ASO) in detection of the 
most common mutation F508del in cystic fibrosis. Black dot denotes hybridization of target DNA 
sequence with the probe and clear dot denotes no hybridization of target DNA sequence with the 
probe. 
 
1.4.3. Allele-specific amplification (ASA) 
 
Allele-specific amplification (ASA), also called allele-specific PCR (AS-PCR) is a PCR 
method used to detect known point mutations or known polymorphisms at the same locus. 
The method bases on the fact, that only a primer with exactly the same sequence as the 
target DNA will be amplified and primers that have a mismatch at the 3’ terminal nucleotide 
will not be elongated during PCR reaction. Allele-specific primers are designed to match, at 
their 3′ ends, the two variants (A/B) at the polymorphic site. The genotyping is run in two 
complementary PCR reactions, one containing one allele-specific primer (e.g. wild-type 
specific) and the common reverse primer and the other containing the other allele-specific 
primer (e.g. mutant specific) and the common reverse primer (Fig. 4). DNA polymerase used 
in this assay must lack the 3’→5’ proofreading activity, so as to not eliminate the 3’ 
mismatch. Described detection method based on AS-PCR is also known as amplification 
refractory mutation system (ARMS) [4, 8]. 
normal ASO
F508del ASO
heterozygote
(carrier)
normal
homozygote
mutant homozygote
(cystic fibrosis)
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Fig. 4. Scheme of allele-specific amplification method. Assay design (A), amplification work flow (B) 
and possible results obtained by electrophoresis (C) or real-time amplification (D) are presented. 
 
Different variants of ASA are currently in use. For example in tetra-primer ARMS-PCR 
method four primers are used in a single PCR reaction, i.e. one pair of inner allele-specific 
(AS) primers and one pair of outer standard primers designed in such a way that the 
amplicons of two alleles differ in sizes and can be resolved by electrophoresis. In allele 
specific primer, near its 3’-end, an additional mismatch may be incorporated in order to 
improve specificity and reliability of ASA. The single nucleotide polymorphism (SNP) 
genotyping assay based on allele-specific amplification may be combined with real-time 
monitoring. Two separate amplifications for the sample, each with one allele-specific primer 
(wild-type or mutant specific) are run with SYBR Green dye and fluorescence is measured by 
the instrument in every amplification cycle to detect the increase of the PCR product 
amount. If an allele is not present, no fluorescence will be detected [4, 8]. 
 
1.4.4. Oligonucleotide Ligation Assay (OLA) 
 
An oligonucleotide ligation assay (OLA) is a rapid and sensitive method for detection 
of known single-nucleotide polymorphism (SNP) alleles. The gene of interest is first PCR 
amplified (in some applications genomic DNA may be used as a template in OLA). The DNA 
template for OLA assay is denatured to form a single-stranded target DNA. Three different 
oligonucleotide probes are used in OLA assay, two Capture Oligo probes, one for each 
genotype, and one Reporter Oligo probe that is modified with phosphate at 5’end (Fig. 5). 
Capture Oligo probes are colour coded, i.e. are labelled with two different fluorescent dyes 
GAllele 1
A
A
G Common primer
Allele-specific primers
Allele 2
(B) Amplification
DNA template
(A) Assay design
PCR 1
first AS primer
+common primer
PCR 2
second AS primer
+ common primer
(C) Results - elelctrophoresis
G G GA A AAS primer
PCR product
Genotype
Sample Patient 1 Patient 2 Patient 3
GG GA AA
R
FU
5      10      15      20      25      30     35     40
Cycle
G/T genotype
G
T
1.0
0.8
0.6
0.4
0.2
(C) Results – real time
 12 
(one for each genotype) and one of them may be additionally size-coded by different length 
of the probe to differ both genotypes during electrophoresis. Oligonucleotide probes anneal 
to their complementary sequences in target DNA and DNA ligase joins two adjacent probes 
at the polymorphic site. Ligation products, labelled with different fluorescent dyes 
depending on the genotype, are separated by capillary electrophoresis coupled with 
fluorescence detection. Different detection formats may also be used (e.g. oligos labelled 
with biotin), nevertheless, main principles are the same [4, 9].  
 
Fig. 5. Oligonucleotide ligation assay (OLA) with fluorescently labelled probes. Scheme represents an 
example of results obtained by capillary electrophoresis of ligation products followed by laser 
excitation and detection of fluorescence emission by CCD camera. Adapted from ref. [9]. 
 
1.4.5. Multiplex Ligation-dependent Probe Amplification (MLPA) 
 
Multiplex ligation-dependent probe amplification (MLPA) is a quantitative method for 
detection of abnormal copy number, resulting from deletions or duplications of certain DNA 
fragments. An advantage of MLPA is that up to 45 different DNA fragments may be analyzed 
in one multiplex reaction. Additionally, in MLPA very small (50-70 nt) sequences are 
targeted, thus the method enables identification of single gene aberrations which are too 
small to be detected for example by FISH. The standard MLPA procedure consists of 
following steps: (a) denaturation of genomic DNA, (b) hybridisation of MLPA probes, (c) 
ligation of between two oligonucleotides, (d) PCR amplification of probes, (e) separation of 
PCR products by capillary-based or sequence gel-based electrophoresis and product 
Allele 1
A
A
G
Reporter Oligo probe
Two Capture Oligo probes
Allele 2
P
T
G
C
FAM
HEX
Hybridization 
and ligation
G
FAM
A
HEX
Capillary
electrophoresis
Ligation products
GG homozygote GA heterozygote AA homozygote
Target DNA 
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quantification, (f) analysis of collected data. Each MLPA probe consists of two 
oligonucleotides that hybridize to adjacent sequence of target DNA. Both oligonucleotides 
can be ligated to each other only if they hybridized to a target sequence, and the ligation 
product is a template for the following PCR amplification. Both oligonucleotides of MLPA 
probe consists of two regions, i.e. a region complementary to an universal primer and a 
region complementary to the target DNA, but the second oligonucleotide is longer and 
additionally, between these two regions, has a stuffer sequence with a unique length (Fig. 
6A). Such MLPA probe design allows us to use only one pair of universal primers in multiplex 
PCR for all MLPA probes used in hybridization. Differences in length of the stuffer sequence 
between different MLPA probes enables identification of various amplicons produced in 
multiplex PCR using capillary electrophoresis separation (Fig. 6B). The forward primer used 
in PCR amplification is fluorescently labelled, thus each amplicon is detected by the means of 
fluorescence measure. The peak area or peak height of each amplicon reflects the relative 
copy number of the target sequence, thus detection of deletions (reduced signal) or 
duplications (increased signal) of regions of interest is possible (Fig. 6C) [10, 11].  
 
Fig. 6. Multiplex ligation-dependent probe amplification (MLPA). Adapted from ref. [10]. 
 
Target A Target B
primer X 
sequence
stuffer sequence
primer Y 
sequence
hybridisation
sequence
hybridisation
sequence
ligation
Target A Target B
PCR amplification
(A) MLPA probe design
(B) Assay
Normal control Deletion(C) Results
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1.4.6. Single-strand conformation polymorphism (SSCP) 
 
Single-strand conformation polymorphism (SSCP) is a method based on 
electrophoresis used for rapid detection and screening of point mutations in DNA fragments. 
The SSCP procedure involves amplification by PCR of a specific DNA fragment, that, next, is 
denatured by high temperature in presence of denaturing agents such as formamide, urea or 
sodium hydroxide. Denatured fragments are separated by polyacrylamide gel 
electrophoresis in nondenaturing conditions. The SSCP method uses the property of single-
strand DNA (ssDNA) to form in a solution, under certain conditions, secondary structures 
called conformers. Formation of a specific structure depends on the nucleotide sequence of 
the DNA fragment and this process may be altered by nucleotide substitutions. Small 
differences in DNA sequence (often a single base pair substitutions) result in different 
secondary structures, thus affect the mobility of different conformers through a gel during 
electrophoresis (Fig. 7).  
Standard detection methods use silver staining or radioisotopes. High throughput 
mutation detection using SSCP technique may be obtained by capillary electrophoresis and 
detection of fluorescently labelled DNA fragments. Apart from the detection method, 
fragments with the same nucleotide sequence form the same conformers with the same 
electrophoretic mobility, thus a specific band (or peak) pattern after electrophoresis is 
observed. Conformers formed by DNA fragments carrying a mutation are different and 
exhibit different electrophoretic mobility and the band (or peak) pattern differs comparing 
to DNA with the wild type sequence (Fig. 7).  
 
Fig. 7. Single-strand conformation polymorphism (SSCP) assay performed with PCR products labelled 
with different fluorescent dyes. Depending on the sequence, conformers  differ with the 
electrophoretic mobility during separation by capillary electrophoresis (CE). Adapted from ref. [12].  
Optimal size of PCR-amplified DNA fragments should be in the range of 150-300 bps. 
In this case, the method detects about 80-90% of potential sequence variations. For DNA 
fragments in the rage of 300-450 bps detection rate decreases 80% or lower. Additionally, 
the quality and efficiency of conformers formation depends on many factors such as 
temperature, DNA concentration, ionic strength, gel crosslinking and glycerol concentration 
Allele 1
Allele 2
FAM
HEXFAM
HEX
FAM
HEX
FAM HEX
Normal conformers
Abnormal conformers
CE95°C
Mutation
Capillary electrophoresis run
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in the gel. Nevertheless, the SSCP is an inexpensive and sensitive technique, suitable as a 
scanning method for detection of unknown point mutations in a selected gene fragments.  
 
1.4.7. Heteroduplex analysis (HET) 
 
Heteroduplex analysis (HET) is a screening method to detect sequence variations in 
diploid DNA. DNA from target genes is amplified by PCR followed by a denaturation step. 
During slow renaturation, DNA strand hybridize randomly, i.e. DNA strands with 
complementary sequences (either both with the wild type sequence or both with the 
mutant sequence) hybridize to form homoduplexes, and non-complementary DNA strands 
(i.e. one with the wild type and the other with the mutant sequence) hybridize to form 
heteroduplexes (Fig. 8). Due to a mismatch in the site of a mutation, heteroduplexes differ 
from homoduplexes with conformation, electrophoretic mobility and melting temperature. 
After PCR, heteroduplexes may be analyzed by separation techniques such as conventional 
gel electrophoresis, denaturing high performance liquid chromatography (dHPLC), 
temperature-gradient capillary electrophoresis (TGCE) or recently heteroduplexes may be 
detected directly after PCR by high-resolution melting analysis. Some of the heteroduplex 
detection methods are described underneath. 
1.4.8. Denaturing High Performance Liquid Chromatography (DHPLC) 
 
Denaturing high performance liquid chromatography (DHPLC) is a method for 
identification of mutations based on heteroduplex formation between wild-type and 
mutated DNA strands. In DHPLC, heteroduplex molecules are separated from homoduplex 
molecules by ion-pair, reverse-phase liquid chromatography on a special column matrix in 
gradient of denaturing agent and temperature. Heteroduplexes and homoduplexes differ in 
stability under denaturing conditions, thus due to differences in retention of DNA on column 
matrix, heteroduplexes are washed out before homoduplexes and the elution profile is 
characteristic for the mutation change (Fig. 8). DHPLC method is characterized by about 
100% sensitivity, thus it is very useful for the screening of a large number of samples for 
mutations, especially in molecular diagnostics of hereditary cancers characterized by 
heterozygous mutations in suppressor genes where heteroduplex analyses may be applied 
[13]. 
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Fig. 8. Denaturing high performance liquid chromatography (DHPLC). 
 
1.4.9. High resolution melting (HRM) 
 
High resolution melting (HRM) is a post-PCR method, that enables analyses of genetic 
variations (SNPs, mutations, methylations) in PCR amplicons. In this method, the DNA region 
of interest is first amplified by PCR and in the next step, while the temperature rises from 50 
to 95°C, melting of PCR products is conducted. Depending on the sequence variation (i.e. 
mutation or polymorphism within the target sequence), the melting curve of variant 
amplicons is slightly different. Either labeled primers or a saturating DNA dye may be used in 
PCR amplification to detect a change in shape of the fluorescent melting curve. With a high 
quality HRM assay, it is possible to distinguish between heterozygote, recessive homozygote 
and dominant homozygote at the locus of interest (Fig. 9). 
Allele 1 Allele 2
Mutation
Denaturation and 
renaturation
heteroduplexes homoduplexes
and
DHPLC
Retention time [min.]
heteroduplexes homoduplexes
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Fig. 9. High resolution melting (HRM) discriminating between wild-type homozygous, mutant 
homozygous and heterozygous genotypes. Adapted from ref. [14]. 
 
1.4.10.  DNA sequencing 
 
Sequencing is a method for determining the nucleotide sequence of DNA molecule, 
thus it is a very precise method for detection of exact mutations responsible for specific 
genetic disorders. Basic sequencing methods, both developed in 1977, include: 
 Maxam-Gilbert sequencing, a method based on chemical modification of DNA 
followed by cleavage at specific bases 
 Sanger dideoxy sequencing, a method based on selective incorporation of chain-
terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. 
The Sanger dideoxy sequencing method become more dominant because it was more 
convenient comparing to Maxam-Gilbert method and the automation of the sequencing 
process has been developed (in automated DNA sequencer instruments). In general, Sanger 
sequencing method involves following steps: (a) isolation of DNA, (b) PCR amplification of 
the DNA fragment of interest, (c) cycle amplification using mix of standard nucleotides and 
dideoxynucleotides, (d) gel electrophoresis or capillary electrophoresis of amplified 
products. When a dideoxynucleotide incorporates at the 3’ end of synthesized DNA chain, 
the elongation terminates at A, T, C or G depending on the specific dideoxynucleotide that 
was incorporated. Automated sequencing technologies involve the usage of fluorescent dye-
labelled dideoxynucleotides in cycle sequencing reaction. Each of four dideoxynucleotides 
(ddNTPs) is labelled with a different fluorescent dye, thus the reaction generates fragments 
of increasing size, ending with one of four dideoxynucleotides and the exact base is 
determined by the fluorescence colour detected by the sequencing instrument. 
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In 1996, a new sequencing technology, called pyrosequencing, has been developed 
by Mostafa Ronaghi and Pål Nyrén at the Royal Institute of Technology in Stockholm [15]. 
Pyrosequencing is a real-time sequencing method and, as distinguished from Sanger dideoxy 
method, pyrosequencing is based on detection of pyrophosphate release during nucleotide 
incorporation and not chain termination resulting from dideoxynucleotides incorporation. 
Four enzymes are involved in the pyrosequencing reaction, i.e. DNA polymerase, ATP 
sulphurylase, luciferase and apyrase. The method detects pyrophosphate (PPi) release 
accompanying DNA synthesis process. Following enzymatic reactions utilized the released 
pyrophosphate to generate a detectable light emission. The templates for pyrosequencing 
reaction are ssDNA fragments (which usually is one strand of PCR product obtained by 
amplification with biotinylated primer). Such strand binds to streptavidin-coated beads in 
order to remove the other strand by rinsing the bead. The sequencing primer is added and 
the template is introduced into pyrosequencer where the mixture of four enzymes is added. 
Next, dNTPs are added to the reaction sequentially. In a single cycle, one of four 
deoxynucleoside triphosphates (dNTPs) is added with exception that instead of dATP, which 
is a substrate for the luciferase, dATPαS, a nucleotide not recognized by luciferase, is added 
to the reaction, to prevent nonspecific luminescence. After a specific dNTP is added, DNA 
polymerase incorporates the current dNTP only if it is complementary to the current position 
on the DNA template. This incorporation is associated with pyrophosphate (PPi) release. The 
next enzyme, ATP sulphurylase, quantitatively utilize PPi to produce ATP using adenosine 5´ 
phosphosulfate (APS). The formed ATP is next utilized by luciferase to convert luciferin to 
oxyluciferin with accompanying release of light quantum. The release of PPi is stechiometric 
to the number of nucleotides incorporated by polymerase, thus the more the same 
nucleotides are incorporated, the more PPi is released and the more intensive is the light 
signal. Regeneration of the reaction mixture after one cycle is lead due to activity of apyrase, 
an enzyme that degrades ATP and unbound nucleotides after before the reaction begins 
with the next nucleotide in the following cycle. 
The automated Sanger sequencing method is considered as a first-generation 
technology, and recently it has been replaced by high-throughput sequencing technologies 
that are referred to as next-generation sequencing (NGS). Next generation sequencing 
technology has revolutionized genomic and genetic research. In NGS thousands or millions 
of sequences are read in parallel sequencing process, thus, this strategy is suitable especially 
for large-scale, automated genome analyses. 
Different high-throughput sequencing technologies are available on the market: 
Massively Parallel Signature Sequencing (MPSS), Polony sequencing, 454 pyrosequencing 
(Roche), Illumina (Solexa) sequencing, SOLiD sequencing, Ion semiconductor sequencing, 
DNA nanoball sequencing, Heliscope single molecule sequencing, Single molecule real time 
(SMRT) sequencing. Three of them are described underneath. Although all these platforms 
differ in sequencing biochemistry, they all share similar work flows comprising of steps such 
as template preparation (DNA fragment library), immobilization of library fragments, 
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generation of clonally clustered amplicons and sequencing, but, depending on the platform 
used, all these steps may be achieved by different approaches [16-19].  
454 pyrosequencing technology. Template preparation for 454 pyrosequencing 
involves randomly breaking of genomic DNA into smaller size fragments (DNA library), that 
next are ligated with short adaptors providing priming sites for further amplification and 
sequencing. Additionally, B-adaptor contains biotin at its 5’-end that enables the 
immobilization of DNA fragments on the surface of magnetic, 28- m capture beads coated 
with streptavidin. One DNA fragment is captured on one magnetic bead. In the next step, 
DNA fragments are amplified by emulsion PCR (emPCR), a PCR in a water-oil mixture, that 
form a microreactor for each bead, thus the amplification of bead-bound DNA fragment 
takes place independently. After emPCR, hundreds of thousand clonally amplified copies of 
the DNA fragment are immobilized on the bead surface. The emulsion is broken and 
following enrichment, DNA beads are layerd onto a titanium PicoTiterPlate. Only one DNA 
coated bead enters one well on the plate. After enzyme beads and packing beads are added 
sequencing is performed by the pyrosequencing method (described previously). 
Luminescence intensity is detected in real-time by CCD camera [16-19]. This sequencing 
technology is sold by Roche. 
Illumina (Solexa) technology. The technology is based on sequencing-by-synthesis 
method. The DNA fragment library may be obtained by any method and resulting library of 
DNA fragments up to several hundreds of bps is ligated with adaptors. Clonal amplification is 
made by bridge PCR, where forward and reverse primers are fixed to a solid surface inside 
the flow cell channels. DNA fragments are amplified after adding of mixture of PCR reagents. 
After amplification about 1000 copies of ssDNA fragments are created forming a surface 
bound colony (a cluster). Next, sequencing primer is annealed and sequencing reagents, 
containing four reversible terminator nucleotides, are added. Each nucleotide is labelled 
with a different fluorescent dye, thus after incorporation in the current position into DNA 
strand, the fluorescent signal is detected by CCD camera. In one cycle, only one terminator 
nucleotide is incorporated and before the next cycle begins, the 3’ terminator group as well 
as the fluorescent dye of the currently incorporated nucleotide are removed and the 
synthesis cycle is repeated [16-19]. This sequencing technology is sold by Illumina. 
SOLiD technology. The technology is based on sequencing-by-ligation method. 
Depending on the purpose, two different types of DNA fragment library may be produced, 
i.e. fragment library or mate-paired library. DNA fragments are ligated to adapters, next they 
are bound to beads and amplified by emulsion PCR. After amplification, DNA templates are 
modified at the 3’ end, covalently bound do glass slide and the sequencing process by 
subsequent ligation steps begins. First, the sequencing primer is hybridized to adaptor 
sequence and next oligonucleotide octamers labelled with fluorescent dyes and the ligase 
are added. First two nucleotides of the octamer determine the colour of the fluorescent 
label. Three next positions are degenerate nucleotides (thus, 64 different versions for each 
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particular dinucleotide are available) and three last positions are universal bases, that are 
the same for all detector oligonucleotides. In the first ligation cycle with oligonucleotide 
octamers, fluorescence signal determines bases 1 and 2 in the sequence. Each ligation 
reaction provides information about colour of particular dinucleotide. Ligated octamers are 
cleaved after their fifth base that removes the fluorescent label. The next ligation cycle 
begins, in which fluorescence signal of the ligated octamer determines the bases 6 and 7. In 
the third cycle bases 11 and 12 are determined, etc. After a series of such ligation processes, 
the product is removed thus the template is reset and another sequencing primer is 
hybridized to the template DNA. Another round of octamer oligonucleotides ligation is 
initiated and the detected fluorescence signal determines bases -1 and 1 in the first cycle, 
bases 5 and 6 in the second cycle, bases 10 and 11 in the third cycle, etc. Once again, after a 
series of ligations, the product is removed, the template is reset and in the third round of 
ligations, bases 4 and 5, bases 9 and 10, bases 14 and 15, etc. are determined. Five rounds or 
ligation cycles are needed to determine the sequence. Because four different dinucleotides 
may correspond to the same colour, the analysis of the -1 nucleotide (which is a known 
oligonucleotide of the adaptor sequence) enables to determine the whole sequence [16-19]. 
This sequencing technology is sold by Life Technologies. 
 
1.5. Biomarkers 
 
According to National Institutes of Health (NIH), a biomarker is “a characteristic that 
is objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention”. In a 
number of genetic disorders, along with molecular diagnostics, different biomarkers are 
used for screening, risk assessment, diagnosis or monitoring of treatment efficacy. Some 
biomarkers can determine staging or grading of a disorder or may be useful in selection of 
initial therapy. Different types of molecules may be used as biomarkers, i.e. DNA and RNA 
biomarkers, protein biomarkers or metabolites [20]. Examples of biomarkers of selected 
genetic disorders are listed in Table 3. 
 
  
 21 
Table 3. Examples of biomarkers of selected human genetic disorders [20]. 
Disease Biomarker  Description 
Down syndrome Biomarkers include β-human 
chorionic gonadotrophin (hCG), 
alpha-fetoprotein (AFP), 
unconjugated oestriol (uE3), serum 
pregnancy associated plasma 
protein-A (PAPP-A), dimeric inhibin 
A 
Elevated levels of these biomarkers 
enable the prenatal diagnostics for 
Down syndrome 
Muscular dystrophy Creatine kinase (CK) blood levels Diagnostic biomarker of several 
neuromuscular diseases, including 
DMD 
nNOS (neuronal form of nitric oxide 
synthase) 
May be useful in suspecting a 
dystrophinopathy because 
sarcolemmal nNOS is lost when 
dystrophin levels are very low or 
absent [21] 
Muscle-miRNAs in serum (miR-1, 
miR-133, and miR-206) 
microRNAs, specifically expressed 
in muscle cells, are released into 
the blood of DMD patients as a 
consequence of muscle 
degeneration and their amount 
correlate with the severity of the 
DMS disease; 
Cacchiarelli et al. proposed the use 
of muscle-miRNAs as a biomarker 
in diagnostics and possibly for 
monitoring the outcomes of 
therapeutic interventions [22] 
Phenylketonuria Phenylalanie and thyrosine Quantitative measurement of 
phenylalanine and tyrosine in 
neonatal blood samples by tandem 
mass spectrometry 
Niemann-Pick disease 
type A and type B 
 
Cytokine MIP-1α in serum (tested 
in mouse) 
 
A biomarker elevated in serum of a 
mouse model of Nieman-Pick 
disease and reduced to normal 
levels after enzyme replacement 
therapy [23] 
Mucopolysaccharidoses Heparin cofactor II-thrombin (HCII-
T) complex in serum and dried 
blood spots 
HCII-T is elevated up to 25-fold in 
MPS diseases that store dermatan 
sulphate and about 4-fold in MPS III 
that stores heparan sulphate 
comparing to unaffected age-
matched controls, thus, HCII-T may 
serve as an effective biomarker for 
MPS I, II, VI and VII diseases [24] 
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Gaucher disease Chitotriosidase, 
 
Most useful markers to follow 
enzyme replacement therapy; 
chitotriosidase is an enzyme which 
is dramatically elevated in 
symptomatic Gauchers patients 
CC chemokine ligand 18 (CCL18) Plasma levels of CCL18 are elevated 
in plasma or in urine of 
symptomatic patients with Gaucher 
disease and decrease during 
therapy [25] 
Fucosidosis Oligosaccharides Elevated levels of oligosaccharides 
in urine may be detected by mass 
spectroscopy 
Huntington disease The most promising candidates: 
24-hydroxycholesterol in plasma, 
BDNF (brain-derived neurotrophic 
factor) in serum, TGFβ 
(transforming growth factor β), 
interleukins (4, 5, 6, 8, 10, 12, and 
23) in plasma or cerebrospinal 
fluid, clusterin in plasma or 
cerebrospinal fluid 
Different candidates are tested to 
search a good biomarker for 
evaluation of disease progression 
in individuals at the premanifesting 
stage of the disease as well as for 
use in therapeutic trials to monitor 
the effects of treatment [26] 
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2. Model organisms for human genetic disorders 
 
Scientists are using model organisms to study health and diseases, but what are “model 
organisms”? In science, a model is a simplified system that is accessible and easily 
manipulated. So a model organism is a species (animal, plant or microbe) that can be used to 
study certain biological processes. This organisms has been widely studied, are easy to 
maintain and breed in a laboratory settings. They are used to obtain information about other 
species because basic principles of fundamental properties how cells grow, divide, how 
inheritance works, how organism store and use energy are nearly the same in all living 
things. Moreover by studying model organisms scientists are learning more and developed 
new methods for maintaining health, diagnose and treat diseases in humans. Up to date 
model organisms from phages to mice have taught us invaluable lessens about fundamental 
biological processes and disease-causing mutations.  
We can distinguish three major types of model organisms and their characteristics are 
described in Table 4. 
Table 4. Major types of model organisms    
Genetic models Experimental models Genomic models 
 Species that are susceptible 
to genetic analysis 
 They can be breed in large 
numbers and have a short 
generation time, large scale 
crosses can be set up and 
followed over several 
generations 
 Many different mutants are 
generally available and 
highly detailed genetic 
maps can be created 
 Species that are not so 
easy genetically susceptible 
 They have longer 
generation intervals and 
poor genetic maps 
 These species are widely 
used in developmental 
biology, embryos studies 
and manipulation  
 Species chosen as model 
organisms because they 
occupy a significant position 
in the evolutionary tree or 
because of some quality of 
their genome 
  
 When scientists discover that a particular gene is associated with a disease in humans 
the next step is to find out what that gene does in a model organism, which often lead to 
better understanding the cause of a disease and develop potential diagnostic tests and 
treatment. There are many examples how model organisms has an impact on human health. 
Research with bacteria, viruses and yeast bring to light how all living things copying and 
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passing on their genetic material as well as fixing mistakes that get made during this process. 
Studies on yeast let us to understand the sequence of events of cell cycle. This knowledge is 
very important because since than many drugs interfering with cell cycle has been discover 
and use to treat cancer. Yeast have been used also to study gene expression, and deliver 
information about how genes are turn on or off. Another example of crucial discoveries 
where studies in Drosophila and C.elegans lead to learning that genetically controlled cell 
death plays a critical role in cancer and other diseases [1]. Laboratory rats have been used to 
test drugs and genetically engineered mice have been used as a models of many human 
diseases. Some such species and their research applications are described in Table 5 adapted 
from [2].     
Table 5. Models used to study genetic principles and human diseases     
Model organism Common name Research applications 
Saccharomyces cerevisiae Yeast  Cell cycle studies 
 Cancer research 
Drosophila melanogaster Fruit fly  Gene mapping 
 Recombination studies 
 Mutant screens to identify genes 
related to specific functions 
Caenorhabditis elegans Nematode  Development of nervous system 
 Aging process 
 Developmental biology 
Danio rerio Zebra fish  Mapping and identifying genes 
involved in organ development 
Mus musculus Mouse  Genetic principles and human 
disease  
Rattus Rat  Genetic principles and human 
disease 
 
 Drosophila, C.elegans, yeast, bacteria and viruses can provide useful information on 
the fundamental biological role of genes but they cannot deliver the information about 
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effects on gene modification on the development of organs or physiological diseases 
processes that are only found in mammals.  Rodents are the most common type of mammal 
employed in experimental studies. Extensive research has been conducted using rats, mice, 
gerbils, guinea pigs and hamsters. Among these rodents the majority of the studies have 
been performed on mice. It is difficult to make an accurate estimation of the total number of 
mouse mutant lines available in the world today but its more than 3000 [3]. 
2.1. Animal models of human genetic diseases 
 Choice of available models to medical genetics is wide and with the advances in 
molecular genetics animal models of human diseases are becoming more numerous every 
day. Due to the remarkable level of homology between genomes of different organisms 
across evolutionary tree we can learn a lot about molecular mechanisms associated with 
single-gene diseases in humans by studying much simpler organisms such us mice. Similar to 
that of humans, mouse genome had been entire sequenced and many human genes have 
homologs in mice. Naturally occurring animal models of human genetic diseases are rare but 
that kind of mutation can be introduced into corresponding mouse gene using genetic 
engineering technics. We are able to create mice with a mutation or deletion of gene 
responsible for certain disorder [4]. It is also possible to insert human genes into the genome 
of mice (humanized mouse models) to study their physiological role. This mice permit 
functional in vivo studies of human cells and tissues [5]. Creating different kind of models 
allows us analyzed in details the development, physiology and biochemistry of a particular 
disease. A summary  the contribution of mouse models in different areas of disease research 
is presented in Table 6 (adapted with modifications from http://www.nuffieldbioethics.org).  
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Table 6. Mouse models in different areas of disease research 
Disease Mouse model Outcome and limitations 
Diabetes  NOD mouse type I diabetes [6] 
 db/db mouse type II diabetes 
[7] 
 research on genetic pathways 
involves in diabetes and the 
hormonal and metabolic control 
of blood sugar level 
Obesity  mutants available  that 
contribute to obesity under 
different conditions [8] 
 research on the hormonal 
(leptin) and hypothalamic 
pathways of obesity  
Neurological  mutants available that affect 
neuronal growth, 
differentiation and plasticity [9] 
 information about genes 
involved with the development 
of neuronal process, testing new 
therapeutic approaches to 
neurological diseases 
Neurobehavioral  mutants available of 
disturbance in complex 
behavior i.e. learning, memory, 
anxiety, aggression, feeding, 
circadian rhythm [10-12] 
 there are no direct models of 
complex behavior but there are 
many strains with the 
sympthoms similar to psychiatric 
disease in human 
Sensory  mutants available with defects 
in hearing and vision[13, 14] 
 there are many useful models 
of retinopathies and deafness 
Cardiovascular  several mutant models 
available [15-17] 
 some progress in the study of 
atherosclerosis and hypertension 
Cancer  many mutants and strains of 
mice which show significant 
variation in both frequency and 
types of cancer[18-20] 
 tumor formation in the mouse 
does not always correspond to 
that in humans but a lot of drug 
tests and research on the role of 
genes that are responsible for 
causing cancer in mammals  
Musculoskeletal  many myopathy models [21] 
and skeletal disease [22] 
 information about genes 
involved with myopathies and 
better understanding of that 
disease and test potential 
therapies 
Disorders related 
with age 
 mutants available for 
Alzheimer’s [23] and 
Parkinson’s disease [24] 
 better understanding of that 
and other neurodegenerative 
disorders and test new 
therapeutic options 
 
Animal models have an inborn or induced pathology that is equal or homological to 
that one observed in humans, and this is the main reason why models of human genetic 
diseases are so helpful in that type of research. Most of the genetic diseases are very rare 
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and because of that it is very difficult to perform studies on patients. In the opposite to that 
animal model for the rare disease can be bred and used when desired. Moreover it give us 
easy access to samples of tissues and biological fluids of any kind and observations can be 
made at all stages of both the disease and the development of the animal. That kind of 
advantage is especially important for study late onset diseases because we are able to look 
at early pathophysiology before the symptoms occur thus lead us to better knowledge of 
early pathogenesis. Another reason why models are necessary is the ethical issue e.g. when 
we would like to test drugs or therapies it is impossible to do it directly on humans. When a 
model is available it is possible to compare groups of treated and untreated animals over the 
course of different protocols and treatments. Finally, animal models are important because 
of them it is possible to establish a link between a mutant gene and an abnormal phenotype 
sometimes by identification of an abnormal protein function.  
Generally we can classified animal models into one of two categories: 
I. Homologous – when the phenotype results form a genetic  alteration in the 
orthologous genes in both species 
II. Analogous – the phenotype is similar but results from genetic  alteration in 
different genes 
It has to be point out that that kind of classification does not mean that one category of 
models is better than the other, and we have to remember that mutation at the same 
genetic locus in different species can give different phenotypes and maybe it is better to use 
models with the similar pathologies even if they result from different genetic mutation. 
Everything up to what scientific question we would like to address.  
2.2. Frequent human genetic diseases and their animal models 
 
Up to date in many animal clinics we have got a large source of models of human 
genetic diseases. One of them is human obesity syndrome which is a heterogeneous 
autosomal recessive disorder. There have been identify a number of genes in which 
missense or nonsense mutation are sufficient to results in severe early onset obesity thus to 
disruption of normal appetite control mechanism (hyperphagia) [25]. There are two animals 
models which are object of intensive researches with similarities to that kind of syndrome in 
humans. The mutant alleles are obese (ob, Lepob)[26] and adipose (ad, Leprad)[27]. This two 
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mutation have been characterized in the mouse, and this studies give a lots of information 
about protein leptin and its receptor [28]. This protein is a 16-kDa cytokine, which is 
synthesized in adipocytes. Serum level of it regulates the amount of energy stored in fat 
tissue as well as energy consumption. The mouse models of leptin deficiency are useful tools 
to investigate in detailed the role of this protein as well as possible use of it as a drug for 
obesity.  In the Fig. 10 is an example of a mouse model with a mutation in Lep gene. 
 
 
 
 
 
 
 
Fig. 10. Mouse homozygous for the mutation in Lep gene and their control littermates. The mutant 
mice have no functional receptor for the cytokine leptin or do not have it at all. Animals do not 
control their satiety and because of that grows very fat. Several alles have been described in this 
locus with similar phenotypes. Depending on genetic background that mice can also be diabetes. 
Adapted from [29]. 
 
 Another interesting mouse model is homologous model of alkaptonuria [30](Fig.11), 
which is a rare metabolic disorder inherited in autosomal recessive manner. The obvious 
clinical feature of that disease is color of the urine, because its turn black when exposed to 
air. That kind of situation occurs due to the defect in a gene coding  HGD (homogentisate 
1,2-dioxygenase) enzyme which is localized in the 3 chromosome (3q13.33 – OMIM 
ID#607474). The symptoms of the diseases are identical between mice and human but there 
is one exception. Patients suffering from this diseases have ochronosis, thus consequence of 
the accumulation of crystals of homogentisate 1,2-dioxygenase in connective tissues which 
lead to arthritis in elderly specially in the spine and large joints. Ochronosis does not develop 
in mice, however the localization of the genetic defect in the mouse model allowed the 
identification of the chromosomal location in humans [31], as well as its very helpful future 
therapeutic developments.  
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Fig. 11. Mouse on the right suffers from alkaptonuria because its gene encoding enzyme HGD is non-
functional. Adapted from [29]. 
 
 Up to date we have many mouse models for metabolic disorders and they are 
invaluable useful tool to study molecular genetics, pathology and potential therapeutic 
options for that type of disease. One of the examples is ferrochelatase deficiency (Fig.12) 
which is a genetic disorder inherited in recessive manner and results in severe erythropoietic 
protoporphyria. Mutation which cause that phenotype is T to A transversion leading to 
methionine-lysine substitution at position 98 (M98K) of the protein ferrochelatase. This 
point mutation results in severe deficiency in FECH activity (about 2.7-6.3 % of the normal 
level). Lack of the enzyme activity results in hemolytic anemia, photosensitivity, cholestasis 
and severe hepatic dysfunction [32, 33].   
 
 
Fig. 12. Mouse model with ferrochelatase deficiency causing anemia, photosensitivity, cholestasis 
and hepatic dysfunction, this mutation represents a model for human erythropoietic  protoporphyria 
and the severity of the syndrome is influenced by genetic background. Adapted from [29] 
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Another interesting example is a mouse model of Marfan syndrome. All mice 
homozygotes for spontaneous or targeted mutations at the Fibrilin1 locus (Fbn1) are lethal. 
They express a lot of abnormalities include vascular defects, excess bone growth, connective 
tissue hyperplasia and lung emphysema leading to death from embryonic to around 4 
months. Phenotypic expression of the same genetic defect is very strain dependent that 
suggest existence of influence of some genetic modifiers. Fortunately there are models (Fig. 
13) with phenotypic similarities to Marfan syndrome but different etiologies [34].   
 
Fig. 13. Mouse model with recessive mutation strigosus (Npr3stg) with growth abnormality, 
extraordinary long body similar to Marfan syndrome. The phenotypic pathology get worse and 
animal become extremely thin with severe hunchback and elongation. Adapted from [29]. 
 
 We still have difficulties to create animal models with chromosomal abnormalities. 
Mouse trisomies are easy to generate but none of them model any on the human disorders 
because the gene distribution along the chromosomes is different between this species. One 
of the most common trisomy in human population is Down syndrome, so it would be very 
useful to possess a model of this genetic alteration. Fortunately once again we can mimic 
symptoms of the disease and good and relatively accurate models of Down syndrome have 
been engineered. Transgenic mice with large insert of HSA21 have been creating [35, 36]. 
Human chromosome 21 shares a large region of genetic homology with mouse chromosome 
16, but the trisomy of this chromosome is not a good model because the animals die in 
uterus. Moreover not all of the genes are similar because human chromosome 21 have also 
orthologs on mouse chromosomes 17 and 10. In Down syndrome there is a certain region 
(21q21.3-q22.2) which is called critical region. Within this region there is a locus for a gene 
which alteration is connected with learning defects and to create a good model for Down 
syndrome the attention has focused on that region. 
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 The study of human diseases has advanced  in large part due to the discovery or 
creation of immune deficient animal models. This animals are incapable of rejecting 
implanted tissues (xenografts) that means that human cell lines can be inserted and will 
continue to grow in these animals. Immune compromised mice have become a routine and 
valuable research tool in oncology. Cancer cell can be implanted and form tumors in the 
same way as it happened in humans. Nude or athymic mice and rats are missing the thymus 
gland, which is responsible for maturation of T lymphocytes. As a side effect this models are 
characterize by the lack of fur in opposite to Severe Combined Immunodeficiency Disease 
mice (SCID) (Fig.14A). SCID mice are unable to make either T or B cells, thus they are missing 
all of their immune response. These mice have a mutation on the 16 chromosome, and they 
are less likely to reject implanted cells than nude mice, since they are completely without 
immune system. Moreover we are able to generate models with additional alterations i.e. 
with green fluorescent protein (GFP) (Fig.14B), which allows us to have more closer look at 
the particular gene and the effects it can have on the physiology or what is the distribution 
over the body. 
 
Fig. 14. Panel A presets Nude rat and mouse (on the top) and SCID mouse (on the bottom), panel B 
presents mice expressing GFP. Adapted from www.criver.com. 
  
 
This chapter summarized potential role for studying human genetic and different 
disorders in some of model organisms.  In all of them animal models have greatly improved 
A B 
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our understanding of the cause and progression of human genetic disorder and become a 
useful tool for testing potential therapeutic approaches. There are still the main question – 
how relevant to human diseases are in this animal models? We know that some of the 
genetic factors and pathways are shared between animal models and humans and the 
others are completely different. Moreover most of the available animal models are made in 
mice which allows us to mimic some aspects of the particular disease but not replicate all of 
the symptoms. However thanks to the models we are able to look for the answers for a 
specific questions about genetic and disease what will be impossible to achieve without 
them.  
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3. Genetic manipulation of animals 
In biomedical research use of experimental animals have been known for decades to 
investigate aspects of physiology and biochemistry. Artificial manipulations have often been 
limited to examining the effect of altering the animal’s environment or some aspects of its 
phenotype. Traditional genetic manipulation of animals involved selected breeding 
experiments or exposure to powerful chemical such as base analogues, intercalating agents 
or physical agents such as radioactivity were and still are widely used to produce force 
random mutation in the animal genomes. After that process animals with phenotypic 
differences were separated and their genome completely analyzed to determine the genetic 
modification involved with that specific phenotypic changes. Some animals especially 
Drosophila and mice have been particularly suitable to that kind of manipulation.  
 A new era in animal research became when genetically modify animals have being 
introduced. In 1976 Rudolf Jaenisch published [1] the first report of insertion of a SV40 virus 
genetic material into mouse embryos. From that moment it become possible to perform 
genetic alteration no longer randomly but in a direct and specific manner. Few years later in 
1981 Gordon and Ruddle reported [2] birth of a mouse that had been genetically modified 
through microinjection of purified DNA into single-cell mouse embryos. It was the beginning 
of  transgenesis and controlled genetic alteration in animal models. Since then the use of 
genetically modified animals in research have been increasing tenfold for each decade and 
diverse models are available such as transgenic, knockout and conditional knockout, knock-
in, humanized and knockdown animals. This models have many advantages for research 
especially in two areas – gene function studies and animal models of diseases.  
The genetic modification of organisms such as Drosophila, C.elegans, yeast, viruses or 
bacteria can provide useful information on the fundamental biological role of genes. 
Unfortunately using this species we will not get the answer for effects of gene modification 
on the development of organs or physiological processes. Mouse is the most widely used as 
an experimental model for that type of study and for modeling the genetics of human 
disease. It is difficult to make a current estimate of the total number of available mouse 
mutant lines, but there are more than 3000 [3]. 
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Trangenetic animal is produce when foreign DNA is artificially put into the cells of an 
animal. The DNA molecule is called a transgene and depend on our scientific questions what 
we would like to address it may contain one or many genes. Stabile transmission of a foreign 
DNA in the germline of transgenic animal is possible when we insert a transgene into a 
fertilized oocyte or cells from the early embryo. Many transgenetic animals especially mice 
have been created and the technology of transgenesis and its application is under constant 
developing. Moreover the ability to performed specific changes in a predetermined gene 
(gene targeting) has permitted to design of many new animal models of human disease. 
There are several approaches that are routinely used for manipulating the mouse 
genome and generating genetically modified animal models. It is necessary to modify the 
DNA of germline cells that this modification become heritable. Certain cell lines were 
considered to be the optimal targets for introducing foreign DNA for example fertilized 
oocyte, very early stage embryos or embryonic stem cells (ES). To create an embryo with 
permanently altered genome and the foreign DNA will be permanently and irreversible 
incorporated into the genome of a host cells at least 3 steps have to be done: 
1) In vitro gene construct have to be created 
2) The  exogenous DNA have to reach the nucleus of the host cell 
3) DNA have to stabile integrate into host genome and have to be passed without 
any alteration to the next generation  
Gene construct 
 It is possible to create different gene construct that can vary in complexity according 
to the insert. Another features which we can choose is the manner how the desire DNA will 
integrated into a host genome. It can be inserted into a genome of the animal in two ways – 
randomly which is called trangenesis by addition, or designed to be inserted at a specific 
targeted site into the correct position of a determined chromosome called transgenesis by 
homologous recombination . In both cases the structure of the gene construct have to be 
carefully planned and consist the structures to control gene expression, such as: a promoter,  
sides of transcription initiation and termination as well as polyadenylation. All of this is very 
important to avoid problems of uncontrolled expression in the host cell. The different 
 37 
strategies can be used to insert DNA into the cells and they are presented in Table 7 (based 
on [4]). 
 
Table 7. Methods used to insert exogenous DNA penetrate to host cell 
Method Description 
Calcium 
precipitation 
 DNA is precipitated with calcium salt, that kind of material is 
incorporated into endosomes and released into the cytoplasm and 
afterwards enters the nucleus 
 Method is quite simple but very inefficient, much of the DNA is 
degraded in endosome but its work for some cell culture types 
Electroporation  Cells are mixed with DNA in solution and exposed to a sudden, 
powerful electric current, which opens pores in the plasma membrane 
allowing entry of the DNA 
 Widely used, very efficient physical method which can be applied to 
most cell types 
Lipid micelles  Method based on the formation of complexes involving cationic lipid 
molecules of DNA, which protects against the nucleases 
 Applicable to most cell types, simple but less efficient than 
electroporation 
Microinjection  DNA in the solution is physically injected into the cell nucleus 
 It is widely used method in transgenesis for gene addition and is 
considered 100% efficient to carry the DNA into the nucleus of somatic 
cells and widely used for insertion of gene vectors into fertilized oocytes 
with success rate 4-8% of animals born with the transgene integrated 
into the host genome  
 It requires specialized equipment and highly skilled individuals to 
performed microinjection which is the main disadvantage 
Viral vectors  The newest method based on integration of the DNA of interest into a 
genome of a virus that is used to infect cell 
 Viruses used in this technique - SV40 (Simian virus 40), retroviruses, 
lentiviruses 
 High rates of efficiency of expression 
 
 The most widely used method to obtain transgenic mice is pronuclear microinjection 
(Fig.15). To obtain transgenic mice by this route females are superovulated, mated to fertile 
males and sacrificed the next day. From excised oviducts fertilized oocytes are recovered. In 
the next step foreign DNA is microinjected using a micromanipulator into the  pronucleus of 
individual oocytes. Oocytes prepared in that manner are reimplanted into the oviducts of 
foster females and allowed to develop into mature animals. During the procedure transgene 
randomly integrates into chromosomal DNA usually at a single site. As a result of 
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chromosomal integration the transgenes can be passed on to subsequent generations in 
mendelian fashion [5].  
Fig. 15. Construction of transgenic mice by pronuclear microinjection  (Adapted from [6]). 
 
Alternative to that approach is transfer of the foreign DNA initially into cultured 
embryonic stem cells (ES). Mouse ES cells are produced from 3.5-4.5 day postcoitum 
embryos and arise from the inner cell mass of the blastocyst from a suitable mouse strain 
(129). Such prepared cells can be genetically modified while in culture and then injected into 
isolated blastocysts of another mouse strain (e.g. C57B10/J which has a black coat color that 
is recessive the agouti color of the 129 strain). In the next step that prepared blastocyst is 
implanted into a pseudopregnant foster mother. The offspring is a chimera containing two 
populations of cells, but when it is backcross can produce mice that are heterozygous for the 
genetic modification. Interbreeding of heterozygous mutants generates homozygotes 
(Fig.16). 
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Fig. 16. Genetically modified ES cells as a rout for creating transgenetic animals (Adapted from [6]). 
 
Integration of foreign DNA into the host genome occurs with a different efficiency 
depend on the method. It is believed  that integration process occurs as a consequence of 
errors made when the DNA repair machinery of the host cell accidently incorporates 
exogenous DNA molecule [7]. DNA molecule break down randomly, integration of 
transfected DNA typically also occurs in random location in the genome. Incorporated 
exogenous DNA could potentially altered the expression of genes of the host but the 
probability is rare. Although when the integration events occasionally alters endogenous 
gene expression (insertional mutation) producing a recognizable phenotype. That kind of 
situation we called in vivo mutagenesis. The opposite approach is gene targeting in which 
the mutation is introduced into a preselected endogenous gene resulting that all cells 
contain a mutation at the desired locus [8].   
For many applications it is desirable to control the expression of a transgene which 
can be achieved with a tissue specific or inducible promoter. Using molecular biology 
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techniques we are able to create structures which are called transgenesis vectors. This 
structures are composed of nucleic acid and derived from viruses, prokaryotic or eukaryotic 
plasmids that have an ability to carry gene of interest into the host cell nucleus and 
integrated it into the genome. The functional vector should contain:  
1. Promoter and upstream regulatory sequences – region that determine the 
conditions of exogenous gene expression as well as location, promoters can be 
inducible which means that their activation can be mediated by drug or by the 
physiological state of the animals 
2. Coding sequence – genetic information for the mRNA to be formed, it contains 
initiation codon (ATG) as well as stop codon (TAA, TGA, TAG) 
3. Termination/polyA signaling sequence – addition of repetition of adenosine at the 
end of the mRNA provides stability of the molecule and allows its translation 
3.1. Types of genetically modified animals 
 
Transgenic animals 
That type of modified animals possess in their genome exogenous gene which was 
artificially inserted and stably incorporated into the genome of every cell of the organism 
and can be transmitted to their offspring. The first described transgenic mouse had inserted 
sequence of the Maloney leukemia virus [1]. The protocol to obtain such animals are very 
different but in general proper construct of the gene is insert to the fertilized egg cell which 
allows for a random integration of the exogenous gene into the genome of the animal. The 
animal generated from this egg cell is called transgenic founder and is heterozygous for the 
transgene. Transgenic models are widely used in different types of research. We can 
evaluate in vivo the effect of the inserted gene during the developmental stages as well as in 
progress of diseases, studies of mutations, search for therapies. 
Knock-out mice 
 This type of models are widely used to study gene function through the phenotype 
presented due to allelic deletion. The knockout model is obtained by target insertion that is 
performed through the mechanism of homologous recombination and it is not a very 
efficient process [9]. Homologous recombination technique allows the insertion of a 
 41 
determined transgene into a specific locus at the desired part of the chromosome. The most 
common way to delete exons is by the creation of targeted construct, plasmid must contain 
a homologous part of the start of the gene (“left arm”) and a part obtained along the gene 
(“right arm”) [10]. Between that parts of the construct exon must be situated, that is 
important for the functionality of the protein. When that kind of vector will be introduced to 
the host cell these homologous regions will pair with corresponding sequences in the gene 
of interest. There is a dependence that the longer the arms the higher probability that the 
pairing will occur. The combination of both arms should be about 6 and 10 kb [11]. As a 
result of this pairing and a double recombination one in each arm is replaced by transgene 
containing the gene sequence to be introduced. Another important element which the 
construct may possess is a reference sequence of a positive selection gene i.e. NeoR. The 
process of double recombination is performed in ES cell culture and there are different 
protocols for cultivation and maintains of these cells [12]. When the ES cells are selected can 
be transferred by micromanipulation into the interior of murine embryos at about 3-4 days 
of age. The modified cells will attach to the normal one and will contribute to the formation 
of all tissues of the adult mouse which creates chimeric mouse (Fig.16). There are two big 
projects which aim to obtain strains with individual deletions for all genes as well as 
mutation known to be related to syndromes – KOMP (Knock-Out Mouse Project) and 
EUCOMM (European Conditional Mouse Mutagenesis). 
Conditional knock-out 
 Deletion of genes which are essential for development may result in embryonic 
lethality thus mice die in the uterus making difficult to study events that occur after birth 
and impossible to study function of this genes in adult animals. One possible strategy which 
allows to avoid problems with embryonic lethality is conditional deletion system. This permit 
gene deletion under specific conditions. The main strategy is known as Cre-Lox system [9]. 
The Cre enzyme is a recombinase present in the P1 bacteriophage and it is responsible for 
mediation of DNA recombination of regions flanked by sequences loxP [13]. The loxP is a 34 
bp sequence that can have a different orientation. When loxP flanks are in consensus the 
region of DNA between them is excited, but when the flanking sites are in opposite positions 
enzyme Cre reversing it. That kind of situation is possible to obtain in ES cells. The 
conditional control is based on the Cre enzyme, which may have its expression controlled by 
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the promoter and can be inherited form another transgenic animal. The promoter that 
regulates the expression of Cre gene will control the deletion pattern of the target gene 
which can be organ or cell type specific. The promoter may be regulated by drugs, 
physiological state of the animal or cell type.  
The promoters what can be used for different conditions [9]:  
1. Cell specific promoter – Cre recombinase will be express only in a determine cell or 
group of cells i.e. aP2 promoter allows to delete gene of interest only in adipocytes, 
αMHC promoter for deletion in cardiomyocytes, ALB for hepatocytes, Nestin for 
neurons, K5 for epithelial cells of the skin, CD19 for B lymphocytes, Cola1 for 
osteoblasts 
2. Temporal promoter – regulatory sequence for gene expression only at specific period 
or physiological state i.e. CaMKII allows to delete gene in nurons only after birth  
3. Inducible promoter – regulatory sequences which are activated or deactivated by 
exogenous molecules. The most wildly used is the TET operon system of E.Coli [14]. 
With this strategy tet-Cre animals are crossed with loxP animals, and homozygous 
offspring at the determined time of development are receiving tetracycline or its 
analogue, which cause excise the gene of interest 
Knock-in mice  
 This technique allows to introduce new genetic elements into specific site. To achieve 
this after the codon stop sequence of the studied gene an entry site of the ribosome is 
added (IRES – internal ribosome entry site), followed by the cDNA sequence of the reporter 
gene. IRES sequence permits a single molecule of eukaryotic mRNA to code two different 
proteins [15]. The most commonly used reporters are enzyme β-galactosidase and GFP 
(green fluorescent protein)[16]. This technique can be used to study the expression of 
molecules, identifying cells that express and modulate expression. That type of animals also 
are used as a models of different types of disorders [4].   
Mice with the fragments of chromosomes 
 It is possible to create artificial chromosomes such as PACs, YACs, and BACs. With this 
constructs it is possible to introduce to the host cells sequences with hundreds of kb 
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originated from human genome. This technique allows to obtain genetically modified mouse 
with human genes. This humanized mice are useful for the study of the expression of factors 
related to the immune system, identify genes related to human diseases as well as create 
new disease models. Another important use of these animals is the ability to produce human 
antibodies that can be injected into the patients without the possibility of recognition and 
rejection [17]. 
Knock-down mice 
 Constitutive or conditional knock-down of genes is performed using RNA interference 
techniques (RNAi). Long molecules of double-stranded RNA (dsRNA) can be processed into 
small interfering RNA (siRNA) with the action of ribonyclease Dicer. The complex called RISC 
(RNA-induced silencing complex) recognizes and cleaves mRNA complementary to antisense 
siRNA. mRNA which has to be cleaved is rapidly degraded [18]. In mammals dsRNA longer 
than 30 bp provoke global response of protein synthesis inhibition and non-specific 
degradation of mRNA. It is possible to create small synthetic dsRNAs which will serve as a 
triggers for specific breaks of mRNA in animal cells. To make it possible, and to create knock-
down animal we have to design specific vector. Such a construct have to contain a sequence 
that encodes an RNA transcript complementary to the target mRNA as well as hairpin region. 
Forming of shRNA is a key feature for Dicer enzyme to act and form siRNA. This construct 
should be stabile integrated into the genome that allows it to pass through generations. The 
big different between knock-out and knock-down animals is that in the first model the target 
protein is completely absent while in the second one we achieve decries in protein quantity 
up to 90%. Knock-out animals have the sequence responsible for mRNA production deleted 
form the genome, while in knock-down animals the interference process acts during post-
transcriptional phase [19]. In some cases it is not necessary to permanently knock-down the 
target protein, and for that purposes we can obtain the knock-down for specific periods. It 
can be done when we associate the expression of RNAi with an inducible promoter 
controlled by doxycycline (Tet-On inducible expression system)[20].       
 After the creation of the genetically modified animal and before it will serve as a 
proper model for human genetic and disease study it have to be well characterized. This 
type of characterization is called phenotyping, and can be divided into three steps [4]: 
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1. Clinical and morphological characterization – morphological characteristic and 
evaluation of all vital parameters (i.e. hart and respiratory rate, blood pressure, 
behavioral analysis, profile of serum molecules, histological analysis of organs, 
monitoring of growth and development 
2. Molecular characterization – evaluation of DNA, mRNA and proteins, identify the 
region of vector integration into the genome as well as the number of copies inserted 
3.  Pathological characterization    
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4. Treatment of genetic disorders 
Once the people suffering from the genetic disorders are completely investigated to find out 
the exact disease they are affected with, so that the patients are correctly diagnosed, they have 
to be set into the most proper treatment. The cure of genetic diseases is a method of 
combating, ameliorating, or preventing a disease caused by abnormalities in genes or 
chromosomes. It is being developed over the past forty years. Knowledge of the human 
genome sequence and the catalogue of human genes, together with advances in molecular 
biology, protein engineering, and bioengineering, have an enormous impact on the treatment 
of genetic disorders. It is obvious that the understanding of genetic disorder at a molecular 
level is the foundation of reasonable therapy. In the following chapter, we review approaches 
of therapies for genetic diseases, from those well established and being successful 
implemented, to new strategies that are still in the exploration phase and seem likely to be 
employed in the future.  
4.1. The current state of treatment of genetic disease 
Genetic disorders can be treated at various stages and at many levels. Below we describe the 
foundation used or proposed for treatment at each of these levels. These include: from 
classical approaches to advanced forms of treatment, for preventive to symptomatic therapies 
[1-5]. The prophylactic treatment that in which the aim is to prevent the occurrence of the 
disease offers the possibility to identify a predisposition of an individual to a particular 
sickness, even before clinical symptoms are manifest, or to predict the probability of 
occurrence of the disease. When a genetic predisposition has been identified, all that is 
possible in many cases is to predict the probability of disease manifestation. On the other 
hand, predictive diagnosis can provide the opportunity to identify a disease at an early stage 
and start a therapy or take preventive measures. Techniques being used in preventive therapy 
to screen for genetic diseases include: (i) preimplantation diagnoses (i.e. testing for diseases 
on embryos acquired during in vitro fertilization), (ii) prenatal analyses (i.e. testing for disease 
on an embryo or in a fetus before it is born), (iii) newborn screening (i.e. used just after birth 
to identify genetic disorders that can be treated early in life), (iv) carrier testing (i.e. used to 
identify people who carry one copy of a gene mutation that, when present in two copies 
causes a genetic disorder), and (v) presymptomatic testing for predicting adult-onset disorders 
or estimating the risk of developing adult-onset disease [6-9]. Unfortunately, predictive 
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genetic diagnosis may also entail certain dangers as a result of wrong, contradictory or 
undesirable information. Therefore the performance of predictive tests should ever be subject 
to special conditions.  
On the other hand, once symptoms of genetic disorders occur, the symptomatic therapies 
aimed at assisting with the handling of diseases begin. All currently existing symptomatic 
treatments are limited, able to partially alleviate, rather than halt disease signs. They are often 
called supporting treatments, as they are mainly directed to sustaining the strength of the 
patient. Symptomatic treatment is also referred to palliative treatment, designed to relieve 
pain and distress with no attempt to cure.  
Although still most genetic disorders cannot be treated, various developmental studies are in 
progress towards safe and efficient pharmaceutical-, cell- and genetic-based therapies. Some 
of these therapeutic approaches are already moved into clinical trials, while others need 
further detailed investigations. The new prospects offer hope for significant delaying and 
possibly halting these debilitating diseases, which are genetic disorders. 
4.2. Therapeutic strategies  
The objective in treating genetic disease is to eliminate or ameliorate the effects of the 
disorder, basically in two ways: either with classical approaches, belonging to the pre-genetic 
medicine era, where also some sophisticated molecular treatments, such as proteomic therapy 
fits in, or with advanced therapies derived from genetic medicine. 
4.2.1. Classical forms of treatment 
It is obvious that environmental interventions, such as medications, lifestyle or diet 
modifications, may have a huge impact on the management of genetically determined 
diseases. These known as the classical strategies aim basically to prevent organ damage from 
excessive amounts of metabolites generated by the metabolic defect or add substances that are 
not synthesized [2]. Broadly speaking they focused on metabolic manipulation and protein 
augmentation therapy. Among the metabolic manipulations the simplest form is diet 
modification, which include: avoidance, dietary restriction, replacement, diversion, inhibition, 
and depletion (Table 8) [1]. 
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Table 8. Treatment of genetic disease by metabolic manipulation. 
Type of metabolic 
manipulation 
Substance or technique Disease 
Avoidance Antimalarial drugs Glucose-6-phosphate 
dehydrogenase deficiency 
Dietary restriction Phenylalanine 
Galactose 
Lactose 
Phenylketonuria 
Galactosemia 
Hypolactasia 
Replacement Thyroxine  
Biotin 
Biopterin 
Congenital hypothyroidism 
Biotinidase deficiency 
Tetrahydrobiopterine deficiency 
Diversion Sodium benzoate  
Oral resins that bind bile acids 
Drugs that block the intestinal 
absorption of cholesterol 
Urea cycle disorders  
Familial hypercholesterolemia 
heterozygotes 
Inhibition Statins 
 
Allopurinol 
Familial hypercholesterolemia 
heterozygotes 
Gout 
Depletion  LDL apheresis (direct removal 
of LDL from plasma)  
Penicillamine 
Cysteine 
Phlebotomy 
Familial hypercholesterolemia 
homozygotes  
Wilson’s disease 
Cystinuria 
Hemochromatosis 
 
Dietary restriction is one of the oldest and most effective approaches of managing genetic 
disease. The restrictive intake of specific dietary component to diminish the metabolic load on 
defective metabolic step, usually requires lifelong compliance with a severe restricted and 
even artificial diet. Currently, diseases involving more than tens loci are managed in this way 
(e.g. lactose restriction for lactase deficiency; phenylalanine restriction to treat 
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phenylketonuria). Furthermore, the oral replacement of essential metabolites, cofactors, or 
hormones whose syntheses are affected due to a genetic disease is often simple in application 
(e.g. biopterin in tetrahydrobiopterin deficiency, biotin in biotinidase deficiency). Next, 
diversion therapy, which is binding of metabolites blocked up-stream of the metabolic 
hindrance and the enhanced use of alternative metabolic pathways to reduce the concentration 
of a harmful metabolite, is another strategy of treatment of genetic diseases (e.g. the urea 
cycle disorder, where ammonia cannot be removed because of a genetic defect of a urea cycle 
enzyme, in this the administration of large quantities of sodium benzoate diverts ammonia to 
glycine synthesis, which results in hippurate formation being subsequently excreted in the 
urine). Also, the pharmacological inhibition of the activity of the malfunctioning enzyme is 
sometimes used to modify the metabolic abnormalities of genetic errors (e.g. the use of 
allopurinol to inhibit xanthine oxidase and prevent uric acid being formed in gout). Finally, 
the use of chelating agents to treat the genetic diseases is reported. Characterized by the 
accumulation of a harmful compound disorders are sometimes treated by direct removal of 
the compound from the body (e.g. the use of penicillamine for the elimination of cooper in 
Wilson’s disease, cysteine in cystinuria, phlebotomy to alleviate the iron accumulation in 
hemochromatosis). 
4.2.2. Surgical approaches - organ replacement therapy 
Even if more invasive, transplantation has long been used and continues to be utilized to treat 
certain genetic diseases that affect particular organs [1,10]. Although complementary rather 
than competing with other treatment approaches of genetic illnesses, organ replacement 
handling remains a viable therapy that continues to be used extensively to this day. It is the 
‘ultimate genetic medicine’, as apart from the relevant somatic stem cell and differentiated 
cells treatment, it involves replacement of the organ that is malfunctioning secondary to the 
abnormal phenotype. Unless the organ donor and the organ recipient are monozygotic twins, 
the genetic material sequence of the donor will be different from that of the recipient, which 
unfortunately hinders the procedure. Organs transplantation for genetic disorders includes 
replacing the liver, kidney, lung and heart. Organ transplantation has been used successfully 
to treat patients with various deficiencies (such as liver transplantation in tyrosinemia, and 
kidney replacement in Fabry disease), as the genetic defect is specifically expressed in the 
affected organ. This forms of treatment is limited by the nature of the surgical intervention 
involved and by a substantial lack of donor organs. What is more, immunosuppressive 
handling is required both for the transplantation of cells and organs. Ultimately, future 
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alternatives could include generation of a new organ. Various new technologies, including 
xenotransplantation (i.e. transplantation of human organs developed in animals), and 
organogenesis (i.e. the de novo development of organs), all have potential for replacing or 
augmenting organ function [11]. However, biological and immunologic obstacles may delay 
application of these technologies [12]. In another approach, the genetic medicine can be 
designed to regenerate a diseased organ, either by re-engineering tissues by expressing 
embryonic key genes that induce organ development or, in the case of stem cell therapy, to 
generate normal tissues. Details regarding these strategies are discussed in the next sections. 
4.2.3 Advanced methods - the molecular treatment of genetic disease  
The molecular treatment of genetic disease include also approach based on pre-genetic 
medicine, which is the proteomic therapy. The concept underlying this strategy is that transfer 
of proteins, peptides, etc., or acting of chemical molecules on proteins will result in modified 
phenotype for therapeutic approaches. 
Other molecular treatment strategies for genetic disorders include transfer of genetic material 
with the use of somatic stem cells (SSCs) and embryonic stem cells (ESCs) (for entire 
genome transfer), gene transfer (for single gene transfer), and RNA modification (for transfer 
of coding sequences). For each of these strategies, the fundamental approach is to modify the 
gene or its expression in cell, tissue and organ of the affected individual.  
4.2.3.1. Treatment at the level of the protein - proteomic therapy 
Enhancement of mutant protein function with small molecule therapy is being used as 
treatment of genetic disorders at the level of the protein [1]. Small molecules, synthetic or 
natural, such as vitamins, non-peptide hormones, and most drugs are class of compounds with 
molecular weights in the few hundreds to thousands. 
Vitamin-responsive inborn errors of metabolism is one of treatments of genetic disorders at 
the level of the protein. The biochemical defects of a number of metabolic diseases may in 
fact respond to the administration of large amounts of the vitamin cofactor of the enzyme 
impaired by the mutation (e.g. the use of high doses of pyridoxine (vitamin B6) in 
homocystinuria). Furthermore, the small molecules that modify the conformation of 
misfolded mutant proteins were also identified as efficient in genetic disorder treatment. The 
administration of such molecules may be used to overcome a folding defect, as they enable 
mutant proteins to move and/or function normally, or otherwise trick chaperones and other 
specific control systems to accept the misfolded protein (e.g. impairment of the ΔF508 protein 
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binding in the endoplasmic reticulum by the calcium-dependent chaperone as a result of the 
administration of curcumin in cystic fibrosis). In another approach, the small molecule 
therapy is associated with skipping over mutant stop codons (e.g. in cystic fibrosis, 
aminoglycoside antibiotics convert the stop codon to an amino acid, a substitution that 
generates a peptide with nearly normal properties). Also, the concept of protein augmentation 
therapy, i.e. purification of the missing, defective or depleted protein, followed by its 
delivering to the patient is successfully implemented in treatment of genetic disorders, 
including various membrane transport disorders (cystic fibrosis), coagulation disorders 
(hemophilia A, hemophilia B, and Von Willebrand disease), emphysema (ά1-antitrypsin 
deficiency), immune deficiency (severe combined immune deficiency), endocrine disorders 
(growth hormone deficiency, congenital leptin deficiency, and congenital neurogenic diabetes 
insipidus), and lysosomal storage disorders (LSDs) (Gaucher's disease type I, Fabry disease, 
mucopolysaccharidosis I, mucopolysaccharidosis II, mucopolysaccharidosis VI, and Pompe's 
disease). In some cases, the success of protein augmentation depends on how well the protein 
is delivered to the organ in which its function is required. The brain is a particularly difficult 
organ to target, because the access of proteins is limited by a membrane structure called the 
blood-brain barrier (BBB). The BBB inhibits the transfer of proteins and other chemicals 
from the bloodstream into the brain. A similar problem occurs for the eye treatment. Though, 
therapeutic agents can be transported directly to the eye, while is not possible with the brain. 
Protein augmentation therapy is most applicable to treating disorders in which the defective 
protein functions in the extracellular space. The avoidance or inhibition of bleeding episodes 
in patients with hemophilia A by the infusion of plasma fractions enriched for factor VIII is 
the prime example here. Also, replacement of alpha-1-antitrypsin in alpha-1-antitrypsin 
deficiency is described as therapy based on replacing an extracellular protein. On the other 
hand, the protein augmentation therapy involving an intracellular protein replacement can be 
effective only if there is a mechanism to import the protein into impaired cell compartments. 
Such extracellular replacement of an intracellular protein is characteristic for lysosomal 
storage diseases including mucopolysaccharidoses, Sachs disease, for adenosine deaminase 
deficiency, while replacement of an intracellular protein by cell targeting is known for 
modified glucocerebrosidase in Gaucher disease. The concept of this treatment is based on 
principle at which the therapeutic enzyme has to be transferred to its intracellular site by 
means of intramuscular or intravenous administration (e.g. to the lysosomes in LSDs). The 
efficiency of enzyme replacement therapy (ERT) was not very high when implemented, 
though it is significantly improved by use of the modified enzymes, being at the same time 
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less immunogenic as observed before. However, still other problems resulting from treatment 
of genetic disorders with protein augmentation therapy such as requirement of frequent, 
repeated administrations, cost, infections, maintaining venous access to administer the 
enzyme, and supply shortages of the therapeutic agents have to be faced. 
4.2.3.2. Treatment at the level of the cell - cellular therapy 
Cellular therapy acts on stem cells (SCs), either on somatic or embryonic. SCs are 
unspecialized cells that are defined by their capacity for self-renewal and the ability to 
differentiate into specialized cells along many lineages [13]. They naturally occur in two 
forms: (i) somatic stem cells (driven from various fetal and postnatal organs, and are multi- or 
unipotent), and (ii) embryonic stem cells (driven from the inner cell mass of embryos at the 
blastocyst or earlier morula stage, and are pluri- or totipotent, respectively) [14, 15].  
Somatic stem cells can be found in specific tissues in the body, and are usually named on the 
basis of the organ from which they are driven. Basically, two sources of SSCs are described, 
which are hematopoietic and non-hematopoietic cells [16]. Hematopoietic stem cells (HSCs) 
can be found in adult bone marrow and blood and umbilical cord blood. These stem cells are 
regularly used in standard therapies, as they make new blood cells. Adult bone marrow stem 
cells are utilized in bone marrow transplantation (BMT) in the clinic for more than 40 years as 
a means to replenish the body cells that can differentiate into all lymphoid and myeloid blood 
lineages (such as leukocyte refilling in patients suffering from leukemia). It is also worth 
mentioning that the purpose of a bone marrow stem cell transplant for children with genetic 
disorders is to provide special marrow-derived cells, which travel to various organs in the 
body including the liver (Kupffer cells), lungs (alveolar macrophages), skin (Langerhan’s 
cells), spleen (macrophages), lymph nodes (lymphocytes and macrophages), and brain 
(microglia). Furthermore, peripheral blood stem cells can be collected from circulating blood 
and used to treat blood disorders, leukemia and other cancers. A particularly promising source 
of stem cells for treating various disorders is umbilical cord blood. In recent years, the blood 
in the cord has been found to be a rich source of SCs that are less susceptible to rejection from 
a transplant recipient’s body than cells or tissues transplanted from another individual. In 
sum, HSC transplantation from individuals that express the normal gene has been used to treat 
many genetic errors including lysosomal storage disorders, immunodeficiences, 
hemoglobinopathies and leukodystrophies.  
 53 
Besides to HSCs, the non-hematopoietic stem cells (non-HSCs) have also been identified in 
the brain, skin/hair, heart, liver, gut, pancreas and skeletal muscle, known respectively as 
neural stem cells, skin stem cells, intestinal stem cells, etc.  
A second population, called bone marrow stromal stem cells (also called mesenchymal stem 
cells), were also discovered. These non-HSCs are small amount of the stromal cell population 
in the bone marrow, and can create bone, cartilage, fat, cells that support the formation of 
blood, and fibrous connective tissue [17].  
Although so far there are no approved treatments using embryonic stem cells, many attempts 
have been made in order to implement them, inter alia, to the cure of genetic disorders [18]. 
Differentiation of ESCs into usable cells while avoiding transplant rejection, also their ability 
to form tumors are just a few of the hurdles that embryonic stem cell researchers still face. 
Also, technical difficulties in obtaining and culturing these cells, as well as ethical concerns 
regarding the use of human embryos as a source of stem cells have hindered the clinical usage 
of human ESCs (hESCs). The use of human embryonic stem cells as models for human 
genetic disorders has started to address this issue. This has been done either by genetically 
manipulating the cells, or more recently by deriving diseased cell lines identified by prenatal 
genetic diagnosis. These studies are however still contravention as they are important issues 
of human being, the foundation of which is to guarantee the freedom to live, where there are 
no question regarding whether or not a potential human life at the embryonic stage should be 
granted the moral status of a human being. 
In addition to stem cells that are isolated from the body, investigators have found an approach 
to produce stem cells by using various reprogramming techniques in the laboratory. Two such 
reprogramming methods are: (i) the creation of induced pluripotent stem cells (iPSCs) [19], 
and (ii) the use of somatic cell nuclear transfer (SCNT) [20]. The ability to convert somatic 
cells into pluripotent stem cells was one of the most exciting breakthroughs in stem cell 
research that occurred recently, and which has been quickly reproduced in labs across the 
world [19, 21-24]. Scientists have identified a set of four genes (OCT4/POU5F1, SOX2, 
KLF4, and c-MYC/MYC) that, when expressed at the same time, can transform skin cells 
(dermal fibroblasts) derived from an adult human into iPS cells. It is important to notice that 
the induced pluripotent stem cells are phenotypically indistinguishable from human 
embryonic stem cells in terms of their gene expression, cell surface markers, and cellular 
morphology. Similar to the hESCs, the induced pluripotent stem cells are immortal, 
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pluripotent, and capable of expressing genes corresponding to all three embryonic cell layers 
(endoderm, ectoderm, and mesoderm) when induced to differentiate. iPSCs may also be an 
extremely powerful  and invaluable tool for making stem cell lines as disease models. 
Understanding the underlying mechanisms associated with disease, among them with genetic 
disorders, is possible by implementation of iPS cells. Lately, a team of researchers applied 
this technique and developed a panel of human disease-specific iPS cell lines, by collecting 
skin cells and bone marrow-derived mesenchymal cells from patients with one of ten various 
disorders, including immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond 
syndrome (SBDS), Gaucher's disease (GD) type III, Duchenne muscular dystrophy (DMD), 
Becker muscular dystrophy (BMD), Parkinson's disease (PD), Huntington's disease (HD), 
juvenile-onset type 1 diabetes mellitus (JDM), Down syndrome/trisomy 21 (DS), and Lesch-
Nyhan syndrome. Like the original iPS cell lines, the disease-specific iPS cell lines were 
immortal, pluripotent, and capable to express genes characteristic of all three embryonic germ 
cell layers when induced to differentiate [25].  
In 2009, it was demonstrated that creation of iPS cells is possible without any genetic 
modification of the adult cells . Pluripotency of the cells treated repeatedly with certain 
proteins guided into the cells via poly-arginine anchors was obtained, and these iPSC cells 
were given the acronym piPSCs (protein-induced pluripotent stem cells) [26]. In the same 
year, a Canadian-Scottish research team announced a method to create iPS cells using the 
piggyBac transposition, instead of utilization of retroviruses, hereby increasing the potential 
use of iPS cells in human diseases [27].  
iPSCs are an important advance in stem cell research, as they may allow scientists to receive 
pluripotent stem cells demonstrating the potential for therapeutic use. As already mentioned, 
they are also an extremely powerful tool for creating stem cell lines as disease models, 
without the controversial implementation of embryos. Therefore, the promise of somatic cell-
derived iPS cell lines was warmly welcomed by both opponents and proponents of human 
stem cell research. Although, additional questions about the ethical status of iPS cells have 
been raised recently and require consideration. Namely, it has been suggested that like human 
embryonic stem cells, iPS cells can also generate germ cells, ova and sperm cells, what can 
make the hESCs and iPSCs not be as ethically distinct as first suggested. 
A somatic cell nuclear transfer is another way to create stem cells [20]. It uses a human egg 
(oocyte), in which the original nucleus is replaced with the nuclear DNA from a donor cell. 
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The reprogrammed oocyte with the entire complement of DNA is stimulated in the laboratory 
and becomes a blastocyst with the same genetic make-up as the donor. At this stage hES cells 
can be extracted and used to create a cell line culture, enabling investigators to create 
genetically identical tissue for tissue replacement (i.e. in autologous transplantation), and 
disease-specific cell line models. SCNT is a type of reprogramming technique that is also 
used in ‘cloning’ technology. Therefore it is often referred to ‘research or therapeutic 
cloning’. There has been significant controversy about this method, in fact justified, and 
concerning the use of this method for reproductive cloning. 
4.2.3.3. Treatment at the level of the gene - genomic and transcriptomic therapies 
Of all of the therapeutic options for treating of genetic disorders, genomic and transcriptomic 
therapies seem to be the most obvious and prominent. Genomic therapy acts on genes, while 
transcriptomic on transcripts. The principle sounds simple enough: missing or defective genes 
need to be replaced by normal genes that can code for functional proteins. However, despite 
the many animal models of genetic disorders that have been successfully treated at the level 
of a gene, correcting human genetic disorders in this way has been difficult. 
For genetic diseases, gene therapy offers the potential to introduce and express cloned genes 
in the cells of patients in order to overcome the disorder. Basically, there are two strategies of 
gene transfer for genetic disorders: ex vivo and in vivo gene transfer [1, 5].  
Gene transfer ex vivo 
Generally speaking, ex vivo gene therapy means that the cells are modified outside the body 
before being implanted into the patients. In detail, cells to be corrected are drawn from the 
affected individual and subjected to genetic alteration by transfer of cloned genes. The 
successfully transformed cells grown in culture are then introduced for replacement into the 
patient. This approach is only applicable to disorders in which the relevant cells can be 
removed from the body, modified genetically and returned to the patient where they will 
engraft and survive for a long time (e.g. bone marrow cells, skin cells, etc.). Another ex vivo 
approach being used for the applications for genetic diseases includes the implementation of 
corrected cells as sources of a secreted proteins (e.g. in hemophilia A treatment the F8 gene is 
transferred to analogous fibroblasts). 
Gene transfer in vivo 
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In vivo gene therapy involves the genetic modification of cells by introduction of the cloned 
gene directly into cells of the patient. The ‘currier’ containing the therapeutic gene is 
administered either directly to the organ of interest (in situ) or into blood vessels that feed the 
specific organ (in vivo). This approach may be the only possible option where relevant cells 
cannot be cultured in vitro, such as brain cells. Since there is no way of selecting and 
amplifying genetically modified cells, the success of this therapy is highly dependent on the 
overall performance of gene transfer and expression. Although a number of gene transfer 
methods have been developed, most of them are too inefficient for real use in clinics. 
Basically, available methods include chemical (polymers, dendrimers, inorganic 
nanoparticles, etc.), physical (electroporation, gene gun, ultrasound, hydrodynamic pressure, 
etc.), and fusion solutions for utilization of non-viral (receptor-mediated endocytosis) and 
viral gene-transfer vectors. There are five classes of gene-transfer vectors and single 
expression cassette model that are used to treat genetic disorders (Fig. 17).  
Expression cassette 
Usually, the gene is administered within an expression cassette that is composed of 
therapeutic transgene (in the form of cDNA or genomic DNA) flanked at the 5’end by the 
promotor and on the 3’ side by a transcription stop and polyadenylation site (Fig. 17A). 
Efficient gene transfer with the use of expression cassette involves a number of 
complications, which relate to a relevant cell targeting, followed be entry into the nucleus 
where the therapeutic transgene has to be expressed. Though the principle sounds simple, it is 
challenging in practice in fact. To accomplish this, non-viral and viral-gene transfer vectors 
are used.   
Liposome/micelle-based plasmid non-viral vectors 
The non-viral vectors of plasmid DNA, naked or formulated with liposomes, consists of an 
origin of DNA replication and antibiotic resistance gene for production in bacteria (Fig. 17B). 
Naked DNA delivery is performed by a physical method, while delivery mediated by a 
chemical carrier such as cationic polymer and lipid is used to enhance the efficiency of 
transferring the plasmid to nucleus. There have been many attempts, some are still running, to 
correct genetic disorders with non-viral vectors. Several human trials carried out for example 
in hemophilia A or in cystic fibrosis have failed when using this strategy, as transgene 
expression tends to be transient and limited by degradation. Despite, non-viral gene delivery 
systems continue to be explored in certain situations, particularly where viral delivery remains 
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a problem or where repeat administrations increase the risk of an immune response to a viral 
antigen. Aerosolizing plasmid DNA, to enable delivery through inhalation (for example for 
treating the respiratory manifestations of cystic fibrosis), has also been accomplished [28]. 
Viral vectors - adenovirus, adeno-associated virus, retrovirus, lentivirus, pox viruses, 
alphaviruses, and herpes viruses 
Viral vectors are a tool commonly used to deliver unmutated genetic material into target cells 
(Fig. 17C, D, E and F). This procedure can be performed inside a living organism (in vivo) or 
in cell culture (in vitro). Many gene therapy clinical trials rely on adenoviruses, adeno-
associated viruses, retroviruses, lentivirus, pox viruses, alphaviruses, and herpes viruses. 
These viruses differ in how well they transfer genes to the cells they recognize and are able to 
infect, and whether they alter the cell’s DNA permanently or temporarily. The most attracted 
viral vectors are the DNA-based adenovirus and adeno-associated virus vectors (AAV 
vectors), and the RNA-based retrovirus and lentivirus vectors. Adenovirus vector is the ‘gold 
standard’ of gene transfer vectors as it was the first gene transfer vector to be used in vivo to 
treat an hereditary disorder . Adenoviral dsDNA does not integrate into the genome and is not 
replicated during cell division, which limits the broader application of adenoviruses. On the 
contrary, adeno-associated viruses may incorporate its genome (ssDNA) into that of the host 
cell. These features make AAV a very attractive candidate for creating viral vectors for gene 
therapy. It has been shown that AAV vector-mediated gene transfer has corrected the 
abnormal phenotype of several animal models of genetic disorders, as well as in humans, 
including cystic fibrosis, muscular dystrophy, hemophilia B, Canavan disease and Batten 
disease. The drawback of using AAV vectors is its small cargo space available for delivery of 
a therapeutic gene. On the other hand, retroviruses are one of the mainstays of current gene 
therapy approaches. The recombinant retroviruses have in fact the ability to integrate into the 
genome of the target cell in a stable fashion. However, this feature also carriers the risk of 
insertional mutagenesis, which results in cancer. Lentiviruses, a subclass of retroviruses, have 
recently been adapted as gene delivery vehicles thanks to their ability to integrate into the 
genome of non-dividing cells. This unique feature of lentiviruses makes them special, as other 
retroviruses can infect only dividing cells. The viral genome (i.e. RNA) is reverse-transcribed 
when the virus enters the target cell to produce DNA, which is then inserted into the genome 
at a random position by the viral enzyme. Despite the fact that a huge number of laboratory 
successes with viral-mediated gene therapy is observed, this type of treatment continues to be 
in crisis owing to the lack of acceptable systems to deliver therapeutic genes to patients. The 
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further development of viral vectors as gene delivery tools is required to overcome serious 
complications associated with their use. The inserted virus-based vector can be perceived as a 
foreign invader by the immune system. As a consequence, the immune system releases 
antibodies to destroy the virus. The reaction of the immune system to the genetically modified 
virus could be very severe, often leading even to organ failure. In addition, the use of viruses 
as vectors poses a risk of viral spread in the organism resulting in other diseases such as 
cancer, alteration of the inserted virus into its original disease-causing form and genetic 
changes in the reproductive cells. As each approach of gene transfer has some limitations, 
there have been some hybrid methods developed that combine two or more techniques, such 
as mixing viral vectors with cationic lipids or hybridizing viruses. 
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Fig. 17. Gene-transfer vectors used to treat genetic disorders. 
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On the genetic horizon, the modern-day equivalent of genomic therapy is likely to be the use 
of transcriptomic therapy, called also RNA-modification treatment [1, 5]. For individuals 
currying a dominant mutation, introduction of the corresponding wild-type gene is usually not 
sufficient to rescue the disease-associated phenotypes. Rather, in such a case to turn off the 
expression of mutant genes, suppressing transcript levels, or to inhibit the function of the 
mutant proteins their encodes is desired. To achieve this goal, investigators have turned their 
attention to RNA-based approaches, which target the RNA (either pre-mRNA or mRNA) 
transcribed from the dominant negative gene and effectively hinder expression of the mutant 
protein. RNA-based strategies for the treatment of disease are depicted in Fig. 18. They are 
five basic approaches to modifying RNA levels: antisense oligonucleotides (ASO), RNA 
interference (RNAi), trans-splicing, segmental trans-splicing, and ribozymes.  
Antisense oligonucleotides 
In ASO-mediated cleavage of mRNA, short single-stranded DNA (ssDNA) molecules, 
usually between 18 and 30 bases long, are designed to hybridize to specific regions (by 
complementarity) of targeted mRNA (Fig. 18A). The resulting DNA-RNA hybrid complex in 
the cell up-regulates expression of the intracellular enzyme ribonuclease H (RNase H), which 
cleaves RNA in the RNA-DNA hybrid molecules, leading to reduced expression of the 
protein that is encoded by the target. 
RNA interference 
RNAi strategy involves the use of small double-stranded RNA molecules (dsRNA, precursor 
of RNAi), typically 22 base pairs long, with 2-3 nucleotide 3’ overhangs, corresponding to a 
region of the target gene (Fig. 18B). The dsRNA is processed within the cell in such a way 
that it becomes part of an RNA-induced silencing complex (RISC) that recognizes and 
destroys the corresponding target mRNA. 
Spliceosome-mediated trans-splicing 
The third strategy, which is based on trans-splicing phenomenon, differs from both of the 
above ASOs and RNAi. Indeed, except for reduction of expression levels of targets, the 
spliceosome-mediated trans-splicing may also be utilized to modify the genetic repertoire at 
the pre-mRNA level to correct the phenotype. Trans-splicing is a gene-transfer approach that 
targets endogenous pre-mRNA containing an alteration within one of its exons (Fig. 18C). 
Therein, a gene-transfer vector is used for delivery of transgene that is required to replace the 
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exon carrying the disease-associated mutation with a wild-type copy of the exogenous exon. 
The transgene contains a hybridization domain, which is complementary to a region of the 5′ 
flanking intron between the donor and branchpoint sites for RNA splicing, followed by the 
splicing branchpoint, the splice acceptor site, the wild-type exon sequence, and the rest of the 
gene. Spliceosome-mediated trans-splicing results in corrected, wild-type copy of the mRNA 
and thus a corresponding wild-type protein. 
Spliceosome-mediated segmental trans-splicing 
To avoid size limitations associated with gene-transfer methods that involve vectors, a new 
model, namely spliceosome-mediated segmental trans-splicing was established. In this 
approach, the gene is divided into two smaller pieces, which are delivered together using two 
separate gene-transfer vectors (Fig. 18D). The vector carrying the second half of the gene 
contains a hybridization domain complementary to an intron located at the 3′ end of the first 
half of the gene, analogous to that described above, i.e. for trans-splicing. Pre-mRNAs are 
then joined through trans-splicing to create an intact per-mRNA, and further to produce a 
mature mRNA encoding the full length of the wild-type protein of interest. 
Ribozyme-mediated trans-splicing 
Ribozymes are RNA molecules with enzymatic activity that recognizes a particular mRNA 
sequences and cleaves them (Fig. 18E). The structure of ribozymes consists of two regions of 
antisense RNA, containing a hybridization domain followed by a ribozyme nucleolytic motif 
that recognizes a target mRNA and the corresponding wild-type gene sequence. Once 
expressed, the correct ribozyme binds to the target, cleaves the endogenous target molecule 
and replaces the defective exon with a correct sequence, leading to the formation of a wild-
type copy of the mature mRNA. 
Many of these RNA-based strategies have been established in recent years, still numerous 
questions regarding the cellular mechanisms involved in transcript targeting and problems 
related to the delivery of mRNA remain. Because the effective delivery is crucial, the 
breakthrough for RNA-modification therapies for treating of genetic disorders will depend on 
progresses in the development of gene-transfer vectors. In addition, a particular attention with 
respect to the specificity of mRNA-targeting approaches, to ensure that only the gene of 
interest is targeted must be paid. 
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Fig. 18. RNA-modification strategies for genetic disorders. 
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4.3. Looking ahead: gene-inspired drug design and multimodal therapies  
Researchers' ever-increasing knowledge of human genome, particular genes, and their 
disease-associated mutations has inspired various approaches to disease treatment design and 
discovery. Still a lot of scientific work is going on to find out the effective therapies for curing 
genetic diseases. The current treatments are not necessarily mutually exclusive, although in 
the meaning of some genetic investigators successful gene therapy would render other 
therapies redundant. These researchers are very enthusiastic about gene therapy, which has 
shown promising effects in clinical test. It is hoped to cure or improve treatment of genetic 
disorders by replacing the malfunctioned or mutated gene, manipulating or turning off the 
gene causing the disease or stimulate other physical functions to fight the disease. However, 
due to the above-mentioned potential side effects and inadequate proof for efficacy of gene 
therapy it may take some time before it will become available to the wider population of 
patients. On the other hand, by understanding the underlying molecular mechanisms linked to 
disorder, and also due to the fact that gene-based therapeutics continues to evolve, multimodal 
approaches to human genetic diseases are very likely scenario. Irrespectively, it is obvious 
that the future of genetic medicine will require close collaboration and multidisciplinary 
approaches, which certainly will be accompanied by unexpected interesting discoveries. 
Continuous progress in all these areas will certainly lead to the cure, rather than the care, of 
many genetic diseases. 
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